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 Prostate cancer is the cancerous development of the prostate, and develops 
over several years with little or no clinical symptoms. Hence, the detection and 
diagnosis of prostate cancer usually occurs in the late metastatic stage, resulting in 
poor prognosis. One of the most common mutations found in prostate cancer is the 
inactivation mutation of PTEN. This leads to the constitutive activation of PI3K-Akt 
signaling, conferring prostate cancer cells the ability to survive without external 
mitogenic signals. However, current monotherapies targeting the PI3K-Akt survival 
pathway remain ineffective, suggesting that there exists an alternate PI3K-Akt 
independent survival pathway in prostate cancer cells. Increasingly, cancer 
progression and aggressiveness have been found to correlate positively with mild but 
higher than normal oxidative stress, which has been shown to enhance cancer cell 
survivability and chemoresistance. More importantly, the investigation of redox 
signaling in prostate cancer cells has identified the superoxide anion (O2
˙ˉ
) as the key 
reactive oxygen species in enhancing cell survival. 
 In this study, we provide evidence for the role of O2
˙ˉ
 in the activation of the 
PI3K-Akt independent survival signaling in LNCaP, the most widely used in vitro 
model for prostate cancer. LNCaP cells are able to survive and grow in the absence of 
growth factors, but undergo apoptosis upon the shutting down of the PI3K-Akt 
pathway by LY294002. However, EGF, R1881 and serum were shown to protect 
LNCaP cells from LY294002 induced apoptosis, by maintaining Bad phosphorylation 
and/or upregulating Bcl-xL expression. In this study, the roles of the Bcl-2 family 




LNCaP survival was enhanced by maintaining Bad phosphorylation at serine 75, 
upregulating Bcl-xL expression and preventing Bax/Bak translocation and activation.  
Superoxide was shown in this study to be able to protect LNCaP cells against 
LY294002 induced apoptosis. This was achieved by preventing Bax/Bak activation 
via the defined parameters: maintaining Bad serine 75 phosphorylation, increasing 
Bcl-xL expression and preventing Bax activation. We also show evidence that Pim-1 
was the main effector in O2
˙ˉ
 signaling; maintaining Bad serine 75 phosphorylation. 
This was consistent with reports of Pim-1 being a prognostic marker in prostate 
cancer. Also, we have demonstrated for the first time that NHE-2 is required for Bax 
activation in LNCaP cells, and that NHE-2 mediated Bax activation is prevented by 
O2
˙ˉ
 signaling. In summary, this study has highlighted the crucial role of O2
˙ˉ 
in the 


















List of Figures 
Figure 1: The hallmarks of cancer ................................................................................. 2 
Figure 2: The Bcl-2 protein family ................................................................................ 9 
Figure 3: BH3-only proteins can engage apoptosis via many different cellular 
processes ...................................................................................................................... 11 
Figure 4: Direct activation and displacement model ................................................... 16 
Figure 5: Bcl-xL dependent Bax retrotranslocation..................................................... 18 
Figure 6: Graphical representation of the NHE-1 protein ........................................... 21 
Figure 7: Production of ROS in cells ........................................................................... 23 
Figure 8: Mechanisms of survival enhancement in LNCaP ........................................ 31 
Figure 9: Role of Bad in LY294002 induced cell death .............................................. 52 
Figure 10: LY294002 treatment results in increased Bax translocation and activation
...................................................................................................................................... 55 
Figure 11: Bax is required in LY294002 induced cell death ....................................... 57 
Figure 12: Bax and Bak are involved in LY294002 induced apoptosis ...................... 61 
Figure 13: Bcl-xL downregulation is required for LY294002 induced apoptosis ....... 63 
Figure 14: Mechanism of LY294002 induced apoptosis ............................................. 65 
Figure 15: Serum prevents LY294002 induced apoptosis ........................................... 67 
Figure 16: Serum rescues LY294002 induced cell death in LNCaP cells ................... 70 
Figure 17: Serum can increase Bcl-xL expression ...................................................... 72 
Figure 18: Serum maintains Bad phosphorylation....................................................... 74 
Figure 19: Serum prevents Bax activation and translocation induced by LY294002 . 77 
Figure 20: Serum prevents apoptosis in LNCaP cells ................................................. 78 
Figure 21: Decrease in superoxide can bypass serum protection ................................ 81 
Figure 22: Superoxide reduction results in loss of serum protection against LY294002 
induced apoptosis ......................................................................................................... 85 
Figure 23: Superoxide and serum are distinct pathways ............................................. 87 
Figure 24: Superoxide promotes Bcl-xL expression ................................................... 89 
Figure 25: Superoxide maintains Bad phosphorylation ............................................... 93 
Figure 26: Pim-1 can phosphorylate Bad at serine 75 in LNCaP ................................ 96 
Figure 27: DPI, quercetagetin and removal of serum can lower phosphorylated Bad 
levels .......................................................................................................................... 103 
Figure 28: Dephosphorylation of Bad by quercetagetin bypasses serum protection . 107 
Figure 29: Inhibition of Pim-1 by quercetagetin in the absence of Akt results in high 
caspase 3 activity ....................................................................................................... 111 
Figure 30: DPI sensitizes LNCaP cells to cell death by causing Bax conformational 
change ........................................................................................................................ 114 
Figure 31: DPI induced intracellular acidification can be rescued by DDC .............. 119 
Figure 32: Inhibition of NHE by EiPa results in intracellular acidification and lowers 




Figure 33: Inhibition of NHE by EiPa removes protective effect of serum against 
LY294002 induced cell death .................................................................................... 124 
Figure 34: EiPa treatment results in increased Bax activation .................................. 127 
Figure 35: Inhibition of NHE-1 by cariporide results in intracellular acidification but 
is unable to sensitize cells to LY294002 induced cell death ..................................... 130 
Figure 36: NHE isoform expression in LNCaP ......................................................... 132 
Figure 37: Loss of NHEs 1 and 2 results in intracellular acidification ...................... 135 
Figure 38: Loss of NHE-2 results in increased Bax activation .................................. 138 
Figure 39: NHE-2 prevents Bax activation and intracellular acidification ................ 140 
Figure 40: Cytoplasmic C-terminus amino acid sequences of NHE isoforms expressed 
in LNCaP ................................................................................................................... 142 
Figure 41: Pim-1 inhibition of quercetagetin has no effect on pH and NHE activity 143 
Figure 42: NHE-2 plays a more important role in the regulation of pH in LNCaP than 
NHE-1 ........................................................................................................................ 146 























BSA Bovine serum albumin 
CM-H2DCFDA 5-(and-6)-chloromethyl-2’,7’-dichlorofluorescin diacetate 
DDC Diethyldithiocarbamate 
DMSO Dimethylsulfoxide 
DPI Diphenylene iodonium 
EiPa Ethylisopropylamiloride 
FBS Fetal bovine serum 








 Superoxide anion 
PBS 
PDK1 
Phosphate buffered saline 
Phosphoinositide-dependent kinase-1 







PI3K Phosphoinositide 3’-kinase 
Q Quercetagetin 
RLU Relative luminescence unit 
ROS Reactive oxygen species 
RPMI Roswell Park Memorial Institute 
SOD Superoxide dismutase 
1 
 
CHAPTER 1: INTRODUCTION 
1.1 CANCER BIOLOGY 
Cancer is a disease that involves uncontrolled cell growth, often resulting in 
the invasion of adjacent tissues and impeding of function. These cells sometimes have 
the ability to metastasize; having the ability to travel to other parts of the body, 
invading different micro environments, often leading to multiple organ failure and 
ultimately, death. According to the World Health Organization (WHO), cancer is the 
leading cause of death in developed countries, and the second leading cause of death 
in developing countries (Ferlay et al., 2010). Cancer is becoming more prevalent as 
the world population grows and ages, especially in developing countries where people 
are starting to lead sedentary lifestyles, eat processed food and smoke more. Thus, it 
comes as no surprise that researchers are interested in this disease and resources are 
used to understand and ultimately, find a cure for cancer. 
The uncontrolled cell growth leading to cancer can originate from different 
cell types, such as haemopoetic cells, epithelial cells or mesenchymal cells. There are 
hundreds of different types of cancers; even different sub-types within specific 
organs. One of the common features amongst the various types of cancers is the 
dynamic changes that occur within the genome, bringing about mutations in key 
cellular process such as proliferation, apoptosis and homeostasis. It is now known that 
these mutations must affect at least six physiological capabilities of the cell in a 
dynamic multistep manner in order for a normal cell to progress to a cancerous 
phenotype (Hanahan and Weinberg, 2000). A normal cell has to acquire the ability to 
multiply by becoming insensitive to anti-growth signals, developing self-sufficiency 




also be able to evade apoptosis, sustain angiogenesis, and acquire the ability to invade 
tissues and metastasize (Figure 1). In 2010, Hanahan proposed a further four 
biological functions: deregulated metabolism, immune system evasion, unstable DNA 
and inflammation were identified to be key contributors to the cancer phenotype 
(Hanahan and Weinberg, 2011). 
 
 
Figure 1: The hallmarks of cancer 
The 10 hallmarks of cancer proposed by Hanahan. Each of the 10 hallmarks contributes to 
cancer progression and is a result of mutations in normal cells. Also shown are the strategies 
used to disrupt each of the capabilities required for tumour growth and progression. (Adapted 








1.2 SURVIVAL PATHWAYS 
1.2.1 Growth factor signaling 
One of the most important physiological processes of the cell is the ability to 
grow and proliferate. This is achieved by the activation of proliferation and survival 
pathways via growth factor signaling. Growth factors consist of a large group of 
proteins and steroids that have diverse functions such as regulating proliferation, 
immune response, differentiation, survival and cell migration. Two capabilities 
acquired by cancer cells in tumour progression involve growth factors; cells must be 
able to proliferate in the absence of growth factors, and/or be self sufficient in the 
generation of growth signals (Hanahan and Weinberg, 2000). Well known growth 
factor signaling pathways include the mitogen-activated protein (MAP) kinase 
pathways and the PI3K-Akt signaling pathway. MAP kinases respond to extracellular 
signals such as mitogen and cytokine stimulation, osmotic stress and heat shock, 
regulating a variety of cellular processes such as gene expression, proliferation, 
survival and apoptosis (Pearson et al., 2001). Akt, also known as protein kinase B, is a 
protein kinase that controls several important cellular functions such as transcription, 
glucose metabolism, apoptosis, proliferation and cell migration (Downward, 1998). 
The constitutive activation of Akt is a common feature of many cancers, playing a 







1.2.2 PI3K-Akt signaling pathway 
Phosphatidylinositol-3-kinases (PI3K) contain a src homology 2 (SH2) 
domain that enables their docking to phosphorylated tyrosine residues of activated 
tyrosine kinase receptors (RTK) (Holt et al., 1994). When growth factors bind to their 
RTKs, the phosphorylation of the tyrosine residues result in the recruitment of PI3K, 
causing a conformation change that allows it to phosphorylate PIP2 to PIP3 at the 
plasma membrane. PIP3 then acts as a lipid messenger, allowing proteins with the 
pleckstrin homology (PH) domain to dock and activate downstream signals. Examples 
of proteins containing PH domains that get recruited to the plasma membrane are Akt 
and PDK1; their docking at the membrane brings them to close proximity. In addition, 
the binding of Akt to PIP3 induces a conformational change which exposes its thr308 
residue, allowing PDK1 to phosphorylate and activate it (Downward, 1998). Akt is 
also phosphorylated at ser473 by mTOR/Rictor complex (Raught et al., 2001); 
phosphorylation of Akt at both thr308 and ser473 is required for full activation.  
Activated Akt achieves its role of perpetuating growth and survival by 
transcriptional and non-transcriptional methods. Akt is responsible for the direct 
inactivation of transcription factors such as the Forkhead family (FOXO) as well as 
the indirect regulation of transcription factors such as p53 and NF-kB (Shaw and 
Cantley, 2006). FOXO transcription factors responsible for the upregulation of genes 
involved in apoptosis, once phosphorylated, are sequestered by 14-3-3 and remain in 
the cytosol. Akt also phosphorylates and activates MDM2, which is an E3 ligase 
responsible for targeting p53 for degradation (Song et al., 2005). This leads to 
degradation of p53, an important transcription factor responsible for inducing growth 




expression of pro-survival Bcl-xL and inhibitor of apoptosis proteins (IAPs), is 
indirectly activated by Akt. The phosphorylation of IκB kinase (IKK) leads to its 
activation and breakdown of IκBα, which is an inhibitor of NF-κB. This allows NF-
κB to translocate to the nucleus and activate the transcription of its target genes. Akt 
can also prevent apoptosis by non-transcriptional mechanisms. Akt phosphorylates 
Bad at ser99 (murine equivalent: 136), resulting in its binding and sequestration by 
14-3-3 (Danial, 2008). Phosphorylated Bad is thus unable to translocate to the 
mitochondria where it interferes with the protective effects of pro-survival Bcl-2 
family proteins.  
Active Akt signaling also induces growth and proliferation in the form of 
increased glucose uptake, metabolism and biosynthesis. This is also achieved by 
transcriptional and non-transcriptional methods. FOXO inactivation by Akt 
phosphorylation, besides preventing apoptosis, also results in increased glycolysis. 
Akt also phosphorylates key glycolytic enzymes such as hexokinase and 
phosphofructokinase 2, hence increasing glycolysis and promoting ATP production 
(Robey and Hay, 2009). Furthermore, Akt also phosphorylates and inhibits tuberous 
sclerosis 2 (TCS2), the negative regulator of mTOR (Inoki et al., 2002). The 
activation of mTOR consequently leads to an increase in lipid and protein 
biosynthesis in response to nutrient availability, facilitating cell growth (Raught et al., 
2001). 
Normal cells need mitogenic growth factor signals in order to activate the 
PI3K-Akt pathway. The activation of Akt is kept in check by regulating the levels of 
PIP3 present in the cell. This is achieved by phosphatases such as phosphatase and 




back into PIP2, thus turning off the signal (Li et al., 1997; Maehama and Dixon, 
1998). Aberrations to the regulation of the PI3K-Akt pathway are extremely common 
in cancer development, where cancer cells acquire the ability to self-sustain growth 
independent of growth signals (Luo et al., 2003). This is achieved by various 
mechanisms such as amplification or constitutive activation of Akt signaling, as well 
as the loss of function of PTEN. Indeed, PTEN is often deleted, inactivated or 
downregulated in tumour cells (Simpson and Parsons, 2001; Sansal and Sellers, 
2004). This highlights the importance of PTEN as a tumour suppressor; the loss of 
PTEN seemingly more detrimental in conferring growth autonomy than amplification 
or mutations that allow negative regulation bypass. 
 
1.3 APOPTOSIS 
The ability for a cell to undergo programmed cell death is a key physiological 
capability for the body to remove unwanted or irreversibly damaged cells in a 
controlled manner. This is an important function in preventing cancer cell 
progression, as mutated cells are removed efficiently, thereby preventing tumour 
growth. Apoptosis is thus a key component in cancer progression. The apoptotic 
pathway can be broadly classified under the extrinsic and intrinsic pathway. The 
extrinsic pathway involves the direct transduction of an external signal that activates 
apoptosis. The intrinsic pathway is mediated by the mitochondria, which releases 
cytochrome c when its outer membrane integrity is compromised by pro apoptotic 





1.3.1 The extrinsic and intrinsic pathway 
The extrinsic pathway is triggered by the aggregation of death receptors on the 
cell surface. Death receptors such as CD95/Fas and tumour necrosis factor receptor 
(TNFR) oligomerize upon binding with their respective ligands. The death receptor 
oligomers recruit adaptor proteins via death domains (DD) present on both the 
cytoplasmic tail of the receptors and the adaptors. The adaptors, which also contain a 
death effector domain (DED), recruit procaspases that also possess the DED domain. 
The close proximity of multiple procaspases results in their activation due to their low 
innate proteolytic activity (Muzio et al., 1998; Boatright et al., 2003). The activated 
procaspases then triggers the downstream caspase cascade evident in apoptosis by 
activating executioner caspases like caspase 3. 
Caspases are cysteine dependent proteases that cleave target proteins that 
bring about the apoptotic phenotype (Creagh and Martin, 2001).  The catalytic 
function of caspases can be attributed to the presence of a cysteine residue in all 
caspases. All caspases recognize a tetrapeptide motif and cleave after an aspartate 
residue within this motif. The difference in these motifs confers substrate specificity, 
which defines the roles of caspases in the apoptotic signaling cascade (Timmer and 
Salvesen, 2007). The intrinsic and extrinsic pathways activate different forms of 
initiator caspases (caspase 9 and 8 respectively), which activates executioner caspases 
like caspase 3 via caspase-dependent proteolytic cleavage. These executioner caspases 
then cleave and activate proteins like ICAD, PARP and nuclear lamins which bring 
about the apoptosis phenotype. 
The intrinsic pathway involves the mitochondrion, an important component in 




Cytochrome c is released upon mitochondrial outer membrane permeabilization 
(MOMP). The release of cytochrome c from the intermembrane space of the 
mitochondria can be triggered by events such as DNA damage, oxidative stress, 
absence of growth factors as well as oncogene expression (Alberts et al., 2008). The 
translocation of cytochrome c from the mitochondria to the cytosol allows its binding 
and association with apoptosis protease activating factor 1 (Apaf-1), ATP and 
procaspases 9, resulting in the formation of apoptosomes. The close proximity and 
favourable conformation leads to the activation of caspase 9 which brings about 
apoptosis by activating downstream executioner caspases via proteolytic cleavage. 
 
1.3.2 MOMP and Bcl-2 family proteins 
The release of cytochrome c is controlled by the prevention of MOMP, which 
is regulated by Bcl-2 family proteins known to play a major role in determining cell 
fate (Chipuk and Green, 2008). Members of the Bcl-2 family possess either a pro-
survival or pro-apoptotic function (Youle and Strasser, 2008), and contain conserved 
Bcl-2 homology (BH) regions that define which of the three categories they belong to. 
The pro-survival family (Bcl-2, Bcl-xL, A1, Mcl-1) contain all four BH regions. The 
presence of a highly hydrophobic transmembrane region at the C-terminal enables 
members of the pro-survival family proteins to localize mostly on the membranes of 
organelles. Pro-survival Bcl-2 family proteins share a common three-dimensional 
structure which is important for their heterodimerization with other Bcl-2 family 
members. They possess common BH1, BH2 and BH3 domains that form a 




al., 1997). Pro-survival Bcl-2 proteins function as antagonists of the pro-apoptotic 
family by binding to and inhibiting their function. 
The pro-apoptotic family can be further sub categorized into the multidomain 
(BH1-3) effector group (Bax, Bak, Bok) and the BH3-only group (Bad, Bid, Bim, 
Puma, Noxa, Bik, Bmf, Hrk/DP5, Beclin-1) (Hardwick and Youle, 2009; Shamas-Din 
et al., 2011). MOMP is achieved when multidomain pro-apoptotic Bcl-2 proteins Bax 
and Bak form a proteolipid pore on the outer mitochondrial membrane (Mikhailov et 
al., 2003), while the main function of BH3-only proteins is to respond to cellular 
stress signals and initiate the apoptotic signal. BH3-only proteins have different 
subcellular localization as well as diverse mechanisms of activation, and have 
preferential binding to the different members of the pro-survival Bcl-2 proteins as 
well (Shamas-Din et al., 2011).  
 
 
Figure 2: The Bcl-2 protein family 
The Bcl-2 protein family consists of the anti-apoptotic Bcl-2 proteins, the pro-apoptotic 
BH123 proteins and the BH3-only proteins. The α helices of the proteins are designated and 
the bold lines define the BH domains. ‘TM’ marks the hydrophobic transmembrane domain. 
Bcl-2 proteins play an important role in determining cell fate and survival, and can be 




1.3.3 Regulation of BH3-only proteins 
The number of BH3-only proteins identified has increased over the years and 
there are now 9 known BH3-only proteins. In the direct activation model discussed 
later, BH3-only proteins are further divided into two groups; the activators (Bim, Bid 
and Puma) and sensitizers (Bad, Noxa, Bik, Bmf, Hrk/DP5, Beclin-1). The activators 
directly activate Bax/Bak while the sensitizers play the more traditional role of 
disrupting the sequestration of Bax/Bak by pro-survival Bcl-2 proteins. BH3-only 
proteins are present in different cellular sublocalization; Bim can be found on 
microtubules (O'Connor et al., 1998; Weber et al., 2007); Noxa on the mitochondria 
(Oda et al., 2000; Ploner et al., 2008); Bad in the cytosol (Datta et al., 2000) and Bid 
in the cytosol and nucleus (Li et al., 1998; Luo et al., 1998; Hu et al., 2003). BH3-
only proteins also respond to a variety of cellular stress (Figure 3) such as DNA 
damage, cytokine deprivation, UV irradiation and death receptor activation (Willis 






Figure 3: BH3-only proteins can engage apoptosis via many different cellular processes 
A variety of cellular stresses are able to activate BH3-only proteins. Responding to different 
cellular stresses, there can be more than one BH3-only protein activated. (Adapted from 
Willis and Adams, 2005.) 
 
A robust regulation of the BH3-only protein function prevents unwanted or 
unintentional cell death. This is achieved by multiple restraining mechanisms such as 
transcriptional control (Bim, Puma, Noxa) or post translational control such as 
sequestration (Bad) or activation by truncation (Bid). For example, Puma is 
upregulated upon the activation of p53 under cellular stress, providing the trigger for 
MOMP (Nakano and Vousden, 2001). The inactive form of Bid is cleaved by caspase 
8 in response to the Fas pathway, resulting in the active truncated tBid to activate Bax 
and induce MOMP (Li et al., 1998; Luo et al., 1998). Several kinases have been 
reported to phosphorylate Bad. Bad phosphorylation at serine 75 (murine equivalent: 
serine 112) is attributed to kinases like RSK and Pim-1 (Aho et al., 2004; del Peso et 
al., 1997; Fang et al., 1999; Harada et al., 1999; Scheid et al., 1999; She et al., 2002; 




serine 99 and 118 (murine equivalent: serine 136 and 155) are phosphorylated by Akt 
and PKA respectively (Bonni et al., 1999; Datta et al., 1997; Lizcano et al., 2000; 
Harada et al., 2001). Phosphatases that dephosphorylate Bad include calcineurin 
(Wang et al., 1999), PP2A (Chiang et al., 2001; Chiang et al., 2003) and PP1 (Ayllón 
et al., 2000; Salomoni et al., 2000; Danial et al., 2003; Djouder et al., 2007). 
Phosphorylated Bad is sequestered in the cytosol by 14-3-3, a chaperone that binds to 
phosphoserine and phosphothreonine ligands. The dephosphorylation of Bad has 
recently been proposed to be a multi-tiered process starting from the 
dephosphorylation of serine 75, exposing serine 99 and 118 for further 
dephosphorylation (Chiang et al., 2003). The phosphorylation status of Bad is 
determined by the balance between the Bad kinases and phosphatases (Danial, 2008). 
Upon dephosphorylation, Bad translocates to the mitochondria and binds to Bcl-xL, 
disrupting its interaction with Bak and allowing MOMP (Datta et al., 2000).  
The kinases, phosphatases, transcription factors and proteases involved in the 
regulation of BH3-only proteins are usually also involved in the regulation of other 
cellular processes such as metabolism (Danial, 2008; Bensaad et al., 2006), DNA 
repair (Smith et al., 1995) or dephosphorylation in other signaling cascades (PP2A) 
(Ory et al., 2003). The large number of BH3-only proteins each with differing 
activation and response mechanisms confers versatility to the cell’s response to 
cellular stress, thus creating a robust apoptotic program that can respond effectively 
and correctly to irreversible cellular damage. However, there have been debates on 






1.3.4 Models of Bax/Bak activation 
Bax and Bak are well known members of the multidomain pro-apoptotic Bcl-2 
family and are essential for MOMP. The combined deletion of Bax and Bak leads to 
cellular resistance to multiple apoptotic stimuli (Wei et al., 2001; Lindsten et al., 
2000). The third pro-apoptotic BH1-3 protein, Bok, is less well understood and is 
associated with placental pathologies (Hsu et al., 1997; Ray et al., 2010). Bax can be 
found in the cytosol as monomers whereas Bak is found on the surface of the outer 
mitochondria membrane (Wei et al., 2001). To initiate MOMP, Bax and Bak must 
oligomerize on the outer mitochondrial membrane to form pores (Mikhailov et al., 
2003). Both Bax and Bak must translocate to the mitochondria and undergo 
conformational changes that would enable oligomerization leading to MOMP 
(Antonsson et al., 2000; Annis et al., 2005). Translocation of Bax from the cytosol to 
the mitochondria alone does not lead to MOMP; Bax translocation induced by 
removing survival signals (Valentijn et al., 2003) did not induce MOMP. Thus, 
translocation and activation of Bax and Bak by conformational changes are 
requirements for successful MOMP. The C-terminus contains a tail anchor sequence 
that allows the insertion of Bax and Bak to the outer mitochondrial membrane 
(Lindsay et al., 2011). In fact, almost all of the multi-domain Bcl-2 proteins contain a 
C-terminus anchor which defines their subcellular localization (Lindsay et al., 2011). 
Under normal conditions, the predominantly cytosolic Bax contains a hydrophobic 
groove on its surface that allows the C-terminus tail anchor to remain protected, thus 
preventing mitochondria targeting (Suzuki et al., 2000). The activation of Bax and 
Bak is achieved by the eversion of the BH3 domain which facilitates BH3-BH3 




al., 2010). Recently, it has been proposed that Bax/Bak oligomerization can be 
achieved by either the interaction of multiple dimers or by the formation of 
asymmetrical heterodimers where an activated Bax/Bak protein is bound to the ‘rear 
pocket’ of another activated Bax/Bak protein (Shamas-Din et al., 2011). The detection 
of an activated Bax protein can be achieved by antibodies that recognize N-terminal 




The regulation of MOMP by Bcl-2 family proteins was initially thought to be 
a straightforward process determined by the ratio of pro-survival and pro-apoptotic 
protein expression (Oltvai et al., 1993; Yang et al., 1995). This hypothesis was 
supported by evidence of increased apoptosis upon deletion of pro-survival Bcl-2 
proteins and decreased apoptosis upon deletion of pro-apoptotic proteins (Veis et al., 
1993; Shindler et al., 1997; Motoyama et al., 1995). However, this model is 
inadequate in accounting for the presence of high levels of Bax/Bak in healthy cells 
and the differences in function of the many BH3-only proteins. Indeed, the 
mechanism of BH3-only protein mediated Bax/Bak activation has become the focus 
of research efforts, culminating in the advent of the two main competing models: the 







The displacement model proposes that multidomain pro-apoptotic proteins are 
constitutively active and require continual neutralization by pro-survival Bcl-2 family 
proteins. MOMP and apoptosis are triggered when BH3-only proteins displace 
Bax/Bak from pro-survival Bcl-2 protein binding. The originally sequestered Bax and 
Bak are thus liberated and are able to oligomerize and promote MOMP. In support of 
this model, peptides derived from BH3-only proteins were found to have different 
binding affinities to different pro-survival Bcl-2 members (Chen et al., 2005). These 
peptides were able to bind to their respective pro-survival Bcl-2 proteins and displace 
their interaction with Bax/Bak (Willis and Adams, 2005; Shimazu et al., 2007). In 
addition, Bax and Bak could induce apoptosis in the absence of BH3-only proteins 
like Bim or Bid, indicating their constitutively active nature (Willis et al., 2007). 
However, the physiological relevance of these observations was questioned since 
most of the work involved BH3 peptides and their interaction with 
overexpressed/recombinant pro-survival proteins in solution or in a fixed supporting 
matrix. Also, evidence of Bax binding to the BH3 stapled peptide of Bim (Gavathiotis 






Figure 4: Direct activation and displacement model 
(A) In the direct activation model, activator BH3-only proteins (BH3A) are responsible for 
the activation of Bax/Bak. Sensitizer BH3-only proteins (BH3S) displace activator proteins 
from anti-apoptotic proteins. (B) In the displacement model, Bax/Bak are constitutively active 
and are sequestered by anti-apoptotic proteins that can be displaced by BH3-only proteins. 
(Adapted from Shamas-Din et al., 2011.) 
 
Direct activation  
The direct activation model proposes that BH3-only proteins directly bind and 
activate the multidomain pro-apoptotic proteins. Furthermore, BH3-only proteins are 
classified as sensitizers or activators (Letai et al., 2002). Activator BH3-only proteins 
include Bim, Bid, and Puma whereas Bad, Noxa, Bik, Bmf, Hrk/DP5 and Beclin-1 
make up the sensitizers (Shamas-Din et al., 2011).  In this model, activator BH3-only 
proteins bind to and activate Bax and Bak, and they are either inactive or sequestered 
by pro-survival Bcl-2 proteins. Upon the trigger of apoptosis, sensitizer BH3-only 
proteins, which have a higher affinity for the pro-survival Bcl-2 proteins than the 
activators, displace the sequestration of the activators, thus freeing them for Bax/Bak 




could induce Bak oligomerization (Wei et al., 2000), and was furthered supported by 
evidence of direct Bax activation by Bid and Bim (Letai et al., 2002; Kuwana et al., 
2005; Kim et al., 2006). Bax activated by Bid was also shown to insert and 
oligomerize on artificial membranes and isolated mitochondria (Lovell et al., 2008). 
However, studies conducted using the splice isoforms of Bim yielded varying results; 
BimEL but not BimL, could induce Bax activation and cytochrome c release from 
isolated mitochondria (Terradillos et al., 2002). Also, this model does not account for 
the direct binding of multidomain pro-apoptotic proteins with their pro-survival 
counterparts. 
Attempts were made to reconcile the differences between the two contending 
models and to explain the anomalies seen in each model. Recently, it was discovered 
that Bax shuttles to and from the mitochondria, undergoing a constant flux in its 
localization (Edlich et al., 2011). The retrotranslocation of Bax from the mitochondria 
to the cytosol was enhanced by the overexpression of Bcl-xL, but BH3-only proteins 
could reduce the rate of retrotranslocation (Soriano and Scorrano, 2011). This 
retrotranslocation model accounts for the presence of Bax in the mitochondria of 
healthy cells and ascribes a new translocation function to Bcl-xL, acknowledging the 
binding of pro-survival Bcl-2 proteins on Bax/Bak in the displacement model. It also 
preserves the activating role of BH3-only proteins in the direct activation model, thus 
reconciling the two opposing models. However, it must be noted that while Bcl-2 
proteins play a vital role in Bax/Bak activation, non-Bcl-2 mediated activation is 
possible. There are reports demonstrating that Bax activation can also be brought 
about by direct phosphorylation by kinases such as glycogen synthase kinase-3β 




pH (Khaled et al., 2001; Tafani et al., 2002; Ahmad et al., 2004). Indeed, pH is an 
important difference between a normal and cancerous cell; an understanding of cancer 
cell intracellular pH could elucidate a cancer cell specific pathway in the regulation of 
apoptosis. 
 
Figure 5: Bcl-xL dependent Bax retrotranslocation 
Bax and Bcl-xL constantly cycles from the mitochondria to the cytosol in healthy cells. 
Absence of free Bcl-xL results in further conformational changes in Bax that lead to its 
activation and oligomerization, and finally integration into the mitochondria. (Adapted from 












1.4 Cancer cell metabolism and ph regulation 
1.4.1 Cancer cell metabolism and glycolysis 
In contrast to normal cells, cancer cells require large amounts of ATP to 
maintain normal cellular processes as well as to cater for their rapid growth and 
proliferation. Due to the lack of sufficient oxygen, cancer cells require a different 
metabolic pathway to generate the required ATP. This is achieved by switching from 
the oxygen dependant generation of ATP via oxidative phosphorylation in the 
mitochondria, to the oxygen independent generation through glycolysis and lactate 
fermentation (Kim and Dang, 2006). This phenotype is known as the “Warburg 
effect” (Warburg, 1956), describing the extensive utilization of glycolysis as the main 
source of ATP even under aerobic conditions.  
The increase in glycolysis can be brought about by many pathways. One of the 
most commonly mutated pathways in cancer is the PI3K-Akt pathway (Wong et al., 
2010). One of the key enzymes activated by Akt is hexokinase, which generates 
glucose-6-phosphate (G6P) from glucose. G6P is an important precursor of the 
pentose phosphate pathway, which synthesizes NADPH and 5-carbon pentoses, 
eventually leading to the generation of nucleotides, nucleic acids, fatty acids as well 
as aromatic amino acids (Vander Heiden et al., 2009). In addition, NADPH plays a 
vital role as a reducing agent in not just the above biosynthetic pathways, but also to 
prevent oxidative stress by reducing oxidized glutathione, thus increasing the cell’s 
antioxidant capacity (Cairns et al., 2011). 
Due to the dependence on glycolysis in cancer cells, excessive lactate 




of important enzymes in glycolysis such as hexokinase and phosphofructokinase is 
pH dependent (Wohlhueter and Plagemann, 1981; Spriet, 1991), therefore there is a 
need for cancer cells to mitigate the effects of an acidic intracellular 
microenvironment by increasing the efficiency and/or the rate of extrusion of protons.  
 
1.4.2 Regulation of intracellular pH 
A key mediator of intracellular pH is the family of plasma membrane pH 
regulators, which ensures the maintenance of optimal physiological pH. This family 
consists of four main members, namely the proton pump, sodium-proton exchanger 
(NHE) family, the bicarbonate transporter (BCT) family and the monocarboxylate 
transporter (MCT) (Izumi et al., 2003). Among these regulators, the NHE family is 
the most widely expressed and it is highly efficient in preventing intracellular 
acidification (Counillon and Pouysségur, 2000). The NHE family, which has nine 





. The most well studied isoforms are NHEs 1-3. NHE-1 is 
ubiquitously expressed in all tissue types while NHE-2 and NHE-3 are found in the 
gastrointestinal epithelium and kidney (Tse et al., 1992; Brant et al., 1995; Praetorius 
et al., 2000). NHEs 4 and 5 can be found in the brain and gastrointestinal tract 
(Attaphitaya et al., 1999) and NHEs 6-9 are found in subcellular organelles (Goyal et 
al., 2003; Nakamura et al., 2005; Numata and Orlowski, 2001). NHE-1 has twelve 
transmembrane segments, as well as a short N-terminal domain and a long regulatory 
C-terminal domain, which contains secondary structures that are important for its 
function (Figure 6). NHE-1 has two main functions, one involves the speed at which it 
can extrude H
+




lowered pHi. The detection is achieved by the presence of a “H
+
 modifier site” that 









NHE-1 is ubiquitously expressed in all cell types and regulates intracellular pH by 
exchanging an intracellular proton for an extracellular Na
+
. NHE-1 has 12 intermembrane 
domains and a long cytosolic C-terminus that contains many regulatory domains. 
 
NHE-1 plays an important role in several cellular functions, including cell 
proliferation, cytoskeletal reorganization, cell migration, as well as survival and 
apoptosis (Putney et al., 2002; Meima et al., 2007). A wide range of cell-surface 
receptors regulate NHE-1 activity by causing the modification of the regulatory 
domains present on the C-terminal cytoplasmic domain. The modifications result in 
the changes in affinity of the internal H
+
 transport site that determines how fast 
protons can be pumped out. Inhibition of NHE-1 activity results in cellular 










1.5 ROS SIGNALING AND CANCER 
1.5.1 Sources of intracellular ROS 
The alterations to normal cell metabolism and biosynthesis pathways in cancer 
cells often lead to the increase in production of reactive oxygen species (ROS). 
Indeed, high levels of ROS have been reported in several cases of cancer, and poor 
prognosis is often associated with higher levels of ROS (Esme et al., 2008; Sasaki, 
2006). A diverse class of free radicals, ROS are highly reactive metabolites of oxygen 
generated from the partial reduction of molecular oxygen to form superoxide (O2˙ˉ), 
hydrogen peroxide (H2O2), hydroxyl radical (OH˙ˉ) and peroxynitrite (ONOO-). ROS 
are produced in all mammalian cells as a byproduct of aerobic metabolism.  
ROS can also be generated by the cell for cellular defence. ROS was first 
discovered to be generated by the gp91
phox
 component of the phagocytic NAD(P)H 
oxidases, where they function as a defence against harmful foreign microorganisms 
(Henderson and Chappel, 1996). It was later discovered that NOX complexes were 
also present in non-phagocytic cells (Lambeth, 2004). The NOX complex catalyzes 
the one electron reduction of O2 to O2˙ˉ, using NADPH as the electron donor. 





Figure 7: Production of ROS in cells  
Reactive intermediates are in bold, key antioxidant enzymes are in italics (Temple et al., 
2005). 
 
1.5.2 ROS chemistry 
Superoxide (O2˙ˉ) is generated by a single electron reduction of O2 by leaked 
electrons from the mitochondrial electron transport chain (Cadenas and Davies, 2000). 
Superoxide is subsequently removed either by spontaneous dismutation or by catalytic 
dismutation via superoxide dismutases (SOD), forming H2O2 which readily diffuses 
through membranes. There are two forms of SOD enzymes, namely SOD1 and SOD2. 
The former is found in the cytosol and is Cu/Zn dependent, whereas the latter is found 
in the mitochondria and is Mn dependent. Unlike O2˙ˉ, H2O2 is not a free radical and 





, H2O2 can form the highly reactive OH˙ˉ radical by Fenton 




biomolecules including nucleic acids, proteins and lipids (Halliwell and Gutteridge, 





participating in the Haber Weiss reaction, increasing the availability of Fe
2+
 for 
Fenton reaction to occur. Superoxide can also form the reactive peroxynitrite by 
reacting with NO. 
 
1.5.3 Antioxidant defence 
 High levels of ROS due to external oxidants or internal disregulation in ROS 
production can result in oxidative stress that cumulates in oxidative damage to 
biomolecules. DNA cross-linking, disulphide bond formation in proteins and lipid 
peroxidation can occur and impede cell function. Hence, there is a need to regulate the 
levels of ROS in the cell. This can be achieved by removing ROS via various 
enzymatic and non-enzymatic antioxidant defence mechanisms. As discussed 
previously, enzymatic approaches to the removal of ROS include the dismutation of 
O2˙ˉ by SOD and the reduction of H2O2 by glutathione reductase and catalase. Non-
enzymatic defence mechanisms utilize vitamins absorbed by dietary intake, and 
include ascorbate (vitamin C), a-tocopherol (vitamin E) and carotene. Together with 








1.5.4 ROS as signaling components 
Despite their seemingly destructive nature, ROS can also function as signaling 
molecules; with O2˙ˉ and H2O2 the most widely studied examples. They are relatively 
less reactive than their counterparts, and as such, are able to provide specificity in 
reacting with other molecules. ROS has in fact been shown to mediate diverse cellular 
processes, including cytoskeleton rearrangement, proliferation and cellular senescence 
(Dröge, 2002). The chemistry of ROS signaling largely involves the reversible 
oxidation of target proteins such as protein tyrosine phosphatases and kinases (both 
cytosolic and receptor) as well as cytoskeletal proteins (Pendyala et al., 2009). Indeed, 
low levels of ROS have been shown to regulate protein phosphorylation by kinases 
and phosphatases, transcription factors, growth factor receptors as well as changing 
intracellular calcium levels (Cai et al., 2003; Cave et al., 2006). However, due to the 
transient and unstable nature of ROS, the small and localized concentrations of ROS 
responsible for signaling events are often difficult to isolate and measure accurately.  
Since ROS are involved in important cellular processes like proliferation, 
survival and migration, it is not surprising to find that many cancers have high levels 
of ROS. This phenomenon was observed as early as two decades ago, detected in 
different tumour cells including prostate cancer (Szatrowski and Nathan, 1991; 
Toyokuni et al., 1995). In fact, the detection of high levels of ROS in prostate cancer 
is often associated with poor prognosis. It is logical to attribute the high levels of ROS 
in cancer cells to the deregulation of their antioxidant systems. However, in a counter 
intuitive manner, many cancer cells have been reported to have upregulated 
antioxidant systems, thus creating a paradoxical situation where high levels of ROS 




and Deshmukh, 2008; Schafer et al., 2009). On closer examination, this in fact 
confers cancer cells with an enhanced ability to maintain hyper proliferative signals 
and generate mutations that confer a selective advantage, but at the same time prevent 
oxidative stress that can result in cell death. The delicate redox balance is kept in 
check, and is often the deciding factor in determining cell fate in these cancer cells. 
 
1.6 PROSTATE CANCER 
Prostate cancer, the cancerous development of the prostate, a gland in the male 
reproductive system, develops slowly over many years before clinical symptoms can 
be detected. Prostate cancer cells are dependent on androgen, a male steroid hormone, 
for growth in the early stages of development. As the cancer progresses, metastasis to 
other parts of the body such as the lymph nodes, adrenal glands, liver and lungs is 
common, and it is usually at this stage of development that clinical symptoms 
manifest (Miller et al., 2003). Early stage prostate cancer can be treated by androgen 
ablation therapy, which involves androgen deprivation via pharmacological 
intervention and/or surgical removal. However, androgen ablation has been largely 
ineffective in late stage prostate cancer, with tumours becoming androgen-
independent, leading to recurrence within 2-3 years (Hellerstedt and Pienta, 2002). As 
clinical symptoms cannot be detected until the late stage, prostate cancer is usually 
diagnosed at the stage where androgen ablation is no longer effective, resulting in 






1.6.1 Prostate cancer and androgen receptor 
The androgen receptor (AR) is a nuclear receptor found in the cytosol, where 
it is activated upon binding to androgens like testosterone. Activated AR is 
translocated to the nucleus, where it functions as a transcription factor, regulating a 
wide variety of genes that result in survival, growth, and proliferation. Normal 
prostate cells require androgen to maintain the inhibition of apoptosis, and this 
remains the case during early stage prostate cancer (Feldman and Feldman, 2001). 
The withdrawal of androgen inhibits proliferation and induces apoptosis in early stage 
prostate cancer cells, but as the tumour mutates and progresses, it is able to escape the 
apoptosis mechanism triggered by androgen deprivation (Feldman and Feldman, 
2001). Several genes have been identified to play a key role in the progression of 
prostate cancer: PTEN, p53, Bcl-2 and IAP being the most commonly detected ones 
(Bello-DeOcampo et al., 2001; Heidenberg et al., 1995; Catz and Johnson, 2003; 
Watanabe et al., 2010). These genes play important roles as tumour suppressors, 
serving as checkpoints in cell cycle, apoptosis as well as growth and metabolism.  
 
1.6.2 Prostate cancer and PTEN 
The most commonly mutated gene in prostate cancer is PTEN, which is the 
negative regulator of the PI3K-Akt pathway responsible for converting PIP3 to PIP2. 
Mutations of PTEN are common in prostate cancer, with up to 60% loss of 
heterozygosity detected in studies (Gray et al., 1995; McMenamin et al., 1999; Cairns 
et al., 1997). Loss of PTEN function in prostate cancer is often associated with poor 




85% of primary tumours in contrast to the normal tissues from the same patient 
(Kremer et al., 2006). There is also a correlation between loss of PTEN and 
metastases development (Schmitz et al., 2007). The loss and inactivation of PTEN, 
the negative regulator of the PI3K-Akt pthway leads to the constitutive activation of 
Akt (Majumder and Sellers, 2005). This enhanced expression and activation of Akt is 
a feature of prostate cancer; reports have shown the increase in Akt staining in cancer 
cells compared to normal cells (Liao et al., 2003) as well as a positive correlation in 
phosphorylated Akt to tumour progression (Malik et al., 2002). The increase in PI3K-
Akt signaling controls tumour growth (Shaw and Cantley, 2006), highlighting the 
importance of PI3K-Akt signaling in not just prostate cancer, but other cancers as well 
(Ghayad and Cohen, 2010). Indeed, rational drug design efforts in recent years have 
attempted to target this pathway to improve prostate cancer (Morgan et al., 2009) and 
breast cancer treatment (Ghayad and Cohen, 2010). 
 
1.6.3 Oxidative stress in prostate cancer 
Apart from mutations in key cellular processes, oxidative stress is also 
associated with prostate cancer progression (Khandrika et al., 2009). Recent findings 
suggest that prostate malignancy and progression can be attributed to oxidative stress 
(Chomyn and Attardi, 2003; Dakubo et al., 2006). Oxidative stress has also been 
shown to be inherently present in prostate cancer cells, and is correlated to an 
aggressive phenotype (Kumar et al., 2008). In fact, evidence suggests that androgens 
are responsible for inducing oxidative stress, which confers radiation resistance in 




ROS involved is O2˙ˉ, not as a byproduct of metabolism in the mitochondria, but 
produced in the cytosol via NOX complexes.  
The increase in NOX dependent production of O2˙ˉ could either be a result of 
mutagenic events that facilitate cancer progression, or be the vital perpetuator of 
enhanced cell survival and proliferation.  In view of the dynamic and hostile 
microenvironment cancer cells survive in, it is very likely that the altered metabolism 
and increased oxidative stress despite the presence of robust antioxidant system 
confers a survival advantage, suggesting that the high levels of O2˙ˉ in the cell could 
be the very key that unlocks an alternative survival pathway. This could explain the 
correlation between oxidative stress, aggressiveness as well as chemoresistance. 
Chemotherapy treatment for prostate cancer, which usually involves the inhibition of 
the well defined Akt-PI3K pathway, is ineffective, suggesting the possible existence 
of an alternative survival pathway that is not switched off.  
 
1.6.4 The LNCaP model 
The LNCaP cell line is one of the most widely used in vitro model of prostate 
cancer. It was established from the left supraclavicular lymph node metastasis from a 
fifty year old Caucasian male in 1977 (Horoszewicz et al., 1983). LNCaP cells are 
androgen-sensitive adherent epithelial cells that grow as single cells and aggregates. 
They contain a frameshift mutation in PTEN that leads to the constitutive activation of 
the PI3K-Akt pathway. This results in their ability to survive in the absence of growth 
factors (Tang et al., 1998). The inhibition of PI3K using specific inhibitors like 




cells (Carson et al., 1999; Yang et al., 2003; Chao and Clément, 2006). However, the 
death inducing properties of LY294002 can be neutralized by serum, EGF as well as 
the synthetic androgen methyltrienolone, R1881 (Carson et al., 1999; Yang et al., 
2003; Chao and Clément, 2006). The enhanced survivability can be attributed to the 
increased phoshorylation of Bad and upregulation of Bcl-xL expression. EGF 
mediated survival was dependent on Bad phosphorylation by RSK1 via the 
MAPK/ERK pathway (Chao and Clément, 2006); serum and R1881 mediated 
survival attributed to the overexpression of the pro-survival Bcl-2 protein, Bcl-xL 
(Yang et al., 2003; Sun et al., 2008). These findings highlight the importance of Bcl-
xL and phosphorylated Bad in the regulation of apoptosis in LNCaP. 
As discussed earlier, the activation of Bax/Bak is an important and vital step in 
mediating apoptosis. In addition to activation, Bax translocation from the cytosol to 
the mitochondria is also required for MOMP. In this regard, Bad, which has a high 
affinity to Bcl-xL (Willis et al., 2007) disrupts the sequestration of Bak by Bcl-xL. 
Therefore, maintaining high levels of Bad phosphorylation prevents this, promoting 
survival. Similarly, the overexpression of Bcl-xL prevents Bak activation by 
sequestering available Bak, as well as providing a reservoir of Bcl-xL to counter the 
effects of dephosphorylated Bad. Thus, the overexpression of Bcl-xL is also 
beneficial for survival (Figure 8). In addition, Bcl-xL was also reported to play a role 
in the retrotranslocation of Bax from the mitochondria to the cytosol, further 
highlighting its pro-survival role in the regulation of apoptosis (Edlich et al., 2011). 














LNCaP can bypass LY294002 induced cell death in the presence of EGF, serum and R1881. 
The increased phosphorylation of Bad by EGF and the overexpression of Bcl-xL by R1881 
and serum prevent effective Bak activation, thus enhancing the survivability of LNCaP cells 
against LY294002 induced cell death. The molecular activation of Bax in LNCaP is not well 
understood. 
 
The importance of the PI3K-Akt pathway has been discussed earlier; not 
surprisingly, the inhibition of PI3K by LY294002 can also lead to apoptosis in 
LNCaP. Treatment of LNCaP cells with LY294002 resulted in the dephosphorylation 
of Akt and the decrease in Akt activity (Chao and Clément, 2006). Although serum 
and EGF are able to prevent LY294002 induced cell death, Akt phosphorylation and 
activity remained low even in the presence of serum or EGF. This suggests that there 
is another survival pathway providing LNCaP cells with an alternative means to cell 
survival. The positive correlation between enhanced oxidative stress and LNCaP 
survivability discussed earlier also provide evidence of a ROS mediated survival 
Figure 8: Mechanisms of survival enhancement in LNCaP 










pathway. Taken together, there is a high possibility that there exists a ROS mediated, 
PI3K-Akt independent survival pathway in LNCaP cells. 
 
1.7 AIM OF STUDY 
Given the ineffectual treatment and poor prognosis of prostate cancer today, a deeper 
and more concise understanding of the various survival pathways in prostate cancer is 
vital. While survival parameters such as Bad phosphorylation and Bcl-xL 
overexpression have been established, the molecular mechanism by which they 
prevent apoptosis is still not clearly defined. In particular, the increased amounts of 
O2˙ˉ reported in prostate cancer cell lines indicate a likely role for O2˙ˉ in promoting 
survival that is undefined. The aim of this study is to understand and establish the role 
of O2˙ˉ in the prevention of apoptosis in LNCaP cells. The function of O2˙ˉ in 
regulating the alternative survival pathway will be investigated, followed by the 
elucidation of the regulatory mechanisms that are involved so as to shut down this 
pathway. The understanding of this O2˙ˉ mediated survival pathway, together with the 
current understanding of the different survival pathways, would no doubt provide 
insights or new approaches that would prevent chemoresistance and a more effective 












Phosphate buffered saline (PBS), fetal bovine serum (FBS), RPMI 1640 media, L-
glutamine, sodium pyruvate and trypsin were from Hyclone, Irvine, CA, USA. 
Staurosporine (STS), saponin, bovine serum albumin (BSA) and LY294002 were 
from Calbiochem, San Diego, CA, USA.  Propidium iodide (PI), RNAse A, 
diphenyleneiodonium chloride (DPI), diethythiocarbamate (DDC), poly-L-lysine, 
nigericin, lucigenin and 1 x Somatic cell ATP releasing reagent were from Sigma-
Aldrich, St Louis, LO, USA. Caspase substrates Ac-DEVD-AFC and Ac-LEHD-AFC 
were from AG Scientific, San Diego, CA, USA. Coomasie Plus Protein Assay 
Reagent Kit, Supersignal West Pico Chemiluminescence Substrate and Restore 
Western Blot Stripping Buffer were from Pierce Biotechnology, Rockford, IL, USA. 
HEPES buffer, Trizol reagent and Lipofectamine were from Invitrogen, Calsbad, CA, 
USA. The dyes 2’,7’-bis(2-carboxyethyl)-5-(and-6)-carboxyfluorescein, 
acetoxymethyl ester (BCECF-AM) and 5-(and-6)-chloromethyl-2’,7’-
dichlorofluorescin diacetate (CM-H2DCFDA) were from Molecular Probe, Eugene, 
Oregon, USA. PathScan Phospho-Bad (Ser112) Sandwich ELISA kit and HTScan 
Pim-1 Kinase Assay kit were from Cell Signaling Technology, Inc. (Beverly, MA). 






2.1.2 Cell culture  
The human prostate cancer cell line, LNCaP-FGC (LNCaP), was obtained from 
American Type Culture Collection. Cells were maintained in RPMI1640 media 
supplemented with 10% Fetal Bovine Serum (FBS), 2mM L-glutamine, 1mM sodium 
pyruvate, and 10mM HEPES buffer at 37C and 5% CO2. Prior to treatment, LNCaP 
cells were plated for two days in complete media followed by 24 hours serum 
deprivation. Cells were seeded at 0.45 x 10
6
 per well in 6-well plates (Nunc, 
Rochester, NY, USA), 0.9 x 10
6
 per dish for 60mm dishes (Iwaki, Chiba, Japan) and 
1.8 x10
6
 per dish for 100mm dishes (Iwaki, Chiba, Japan) , to achieve approximately 
70% confluency at the time of treatment.  
 
2.1.3 Drug treatments 
Stock solutions of LY294002 (Calbiochem, San Diego, Ca, USA) and DPI (Sigma-
Aldrich, St Louis, LO, USA) were prepared by dissolving the drugs in DMSO to 
obtain stock concentrations of 0.1M and 25mM respectively. These were then added 
to RPMI media to obtain a final concentration of 25μM for LY and 6μM for DPI.  
Fresh stock solutions of DDC (Sigma-Aldrich, St Louis, LO, USA) (100mM) were 
prepared prior to treatment by dissolving the drug in RPMI media. This was then 
further diluted to obtain a final concentration of 1mM for treatment. Stock solutions 
of quercetagetin (Calbiochem, San Diego, Ca, USA) were prepared by dissolving the 
drug in DMSO to obtain a concentration of 0.1M which was added to media to obtain 
a final concentration of 25μM. Stock solutions of EiPa (Sigma-Aldrich, St Louis, LO, 








Antibodies for Voltage-dependent anion channel (VDAC), Phospho-Akt (Ser473), 
Akt, Bcl-xL, Phospho-Bad (Ser112) and Bad were purchased from Cell Signaling 
Technology, Inc. (Beverly, MA). β-actin monoclonal antibody were from Sigma 
(St.Louis, MO), Bak-NT and Bax-NT antibodies were purchased from Upstate (Lake 
Placid, NY) and Bax6A7 antibody was from BD Biosciences, San Diego, CA, USA. 
Secondary antibodies used were peroxidase-conjugated goat anti-rabbit antibody 
obtained from DakoCytomation (Glostrup, Denmark), goat anti-mouse FITC antibody 
purchased from Molecular Probes, Inc. (Eugene, OR, USA). NHE-1 and Pim-1 
antibodies were purchased from Millipore (Billerica, MA, USA). Cu/Zn Superoxide 
Dismutase (SOD1) and NHE-2 antibodies were from Santa Cruz (Santa Cruz, 
California, USA). An additional NHE-2 antibody was purchased from AbD Serotec, 










2.2.1 Bax activation assay (saponin) 
Cells were serum deprived and treated in 6-well plates (Nunc, Rochester, NY, USA), 
and the media and cells were both collected. The wells were washed once with 1x 
PBS and the cells were pelleted by centrifugation at 2,200rpm for 5mins at 4C, after 
which the pellet is washed once with 1x PBS. The cells were then resuspended in 
100μl cold 1x PBS, followed by fixing by adding 900μl of 0.55% paraformaldehyde 
dropwise and incubating on ice for 30mins. The fixed cells were then centrifuged at 
12,000rpm for 5mins at 4C, followed by washing with 1x PBS(1% FBS) twice. The 
cell pellet was then resuspended with mouse anti-Bax 6A7 antibody in staining 
solution (1% FBS and 0.1% saponin in PBS) at room temperature for 1hr or at 4C 
overnight. The cells were then centrifuged again at 12,000rpm for 5mins at 4C, 
followed by incubation with anti-mouse FITC antibody in staining solution for 
45mins. At least 15,000 events were analyzed for Bax activation using the Coulter 
Epics Elite ESP Flow Cytometer (FL, USA) at the emission wavelength of 525nm. 
 
2.2.2 Bax activation assay (Leucoperm) 
Cells were serum deprived and treated in 6-well plates, and the cells were washed 
with PBS and trypsinized. The collected cells were pelleted by centrifugation at 
2,000rpm for 5mins at 4C, after which the pellet is washed once with 1x PBS. The 
cells were then resuspended in 100μl PBS(1%BSA), followed by fixing by adding 
100μl of Leucoperm reagent A (cell fixation medium containing formaldehyde) and 




2,000rpm for 5mins at 4C following the addition of 3ml PBS(1% FBS). The cell 
pellet was then resuspended with 100μl mouse anti-Bax 6A7 antibody in Leucoperm 
reagent B (permeabilisation medium) at 4C overnight. The cells were then washed 
with PBS(1% FBS) and centrifuged at 10,000rpm for 5mins at 4C, followed by 
incubation with anti-mouse FITC antibody (Molecular Probe Inc, Eugene, OR, USA) 
in reagent B for 45mins. At least 10,000 events were analyzed for Bax activation 
using the BD FACSCanto II flow cytometer (BD Biosciences, San Jose, CA, USA) at 
the emission wavelength of 525nm. 
 
2.2.3 Caspase activity 
Cells were harvested by scrapping them off the wells or dishes and spinning them 
down by centrifugation at 2,200rpm for 5mins at 4C. They were then washed once 
with cold PBS and lysed using cold Cell Lysis Buffer (BD, Biosciences Pharmingen, 
San Diego, CA, USA) for 10mins. The lysates were then stored at -20C until all the 
samples were collected. The lysates were then allowed to thaw on ice, followed by 
centrifugation at 3,800rpm for 5mins at 4C to remove cell debris. Next, 40μl of the 
supernatant was transferred into a 96-well transparent flat bottom microtitre plate 
(Nunc, Rochester, NY, USA) containing 40μl of reaction buffer and 4μl of caspase 
substrate (50μM) (caspase 3 substrate: Ac-DEVD-AFC, caspase 9 substrate: Ac-
LEHD-AFC). The reaction buffer (10mM HEPES, pH 7.4, 2mM EDTA, 6mM DTT, 
10mM KCl and 1.5mM MgCl2) was supplemented with protease inhibitors (1mM 
PMSF, 10μg/ml aproptinin, 20μg/ml pepstatin A and 10μg/ml leupeptin). The 




fluorescence using Spectrafluor- Plus spectrofluorometer (Tecan, GmbH, Grodig, 
Austria) at excitation 400nm and emission 505nm. Caspase activity was normalized 
with protein concentration and expressed as relative fluorescence unit (RFU) per μg 
of protein.  
 
2.2.4 Determination of intracellular pH, NHE activity and proton affinity 
To enhance the adhesiveness of LNCaP cells, 1ml of 30μg/ml poly-L-lysine was used 
to coat 6-well plates for at least 4 hours prior to plating. Subsequently, the wells were 
washed with 1x PBS before seeding with 0.45 x 10
6
 cells and allowed to grow for 2 
days. Following a 24 hour serum deprivation and 1 hour drug treatment, cells were 
washed with 1x PBS and HCO3 free HEPES buffer (135mM NaCl, 5mM KCl, 1.8mM 
CaCl2, 1mM MgSO4, 5.5mM glucose and 10mM HEPES at pH 7.4). The cells were 
then incubated with 5μM 2’,7’-bis(2-carboxyethyl)-5-(and-6)-carboxyfluorescein, 
acetoxymethyl ester (BCECF-AM) in HCO3ˉ free HEPES buffer at 37C for 25mins. 
Next, the cells were washed once with HEPES buffer and the fluorescence of the 
BCECF dye was measured using Spectrafluor- Plus spectrofluorometer (Tecan, 
GmbH, Grodig, Austria) at excitation 485nm and 430nm and emission 535nm. The 
pH standard curve was calibrated by adding high K
+
 buffers of differing pH (6.4, 6.8, 
7.2, 7.6 and 8.0) with 10μM nigericin to cells pre-incubated with BCECF dye for 
25mins, for 4mins before measurement of fluorescence. The K
+
 buffers were prepared 
by mixing a pH 4 buffer (140mM KH2PO4 and 20mM NaCl) and pH 9 buffer (70mM 
K2HPO4 and 20mM NaCl) until the required pH is obtained. The excitation ratio of 
485nm:430nm gives the relationship between fluorescence and intracellular pH. After 




HEPES buffer with HCO3ˉ free HEPES buffer containing 30mM NH4Cl at pH 7.4 for 
8mins, with a measurement taken every minute. The cells were then immediately 
washed with HEPES buffer followed by incubation with Na
+
 and HCO3ˉ free HEPES 
buffer (135mM N-methyl glucamine, 5mM KCl, 1.8mM CaCl2, 1mM MgSO4, 
5.5mM glucose and 10mM HEPES at pH 7.4) for 30s. Following this, Na
+
 free 
HEPES buffer was replaced with HEPES buffer and pH recovery was monitored over 
15mins. NHE-1 activity was determined by the rate of intracellular pH recovery 
within the first 2mins and expressed as a ratio of change in pH and change in time. 
NHE-1 set point was taken to be the first point of the pH recovery. 
 
2.2.5 Bad phosphorylation ELISA assay 
Cells in 6 well plates were harvested, lysed and quantified for protein concentration. 
The lysates were diluted with sample diluent from the kit and 100µl of cell lysate was 
added to a Bad Ab-coated 96-well plate. This was followed by incubation for 2 hours 
at 37C before washing 4x with 200µl 1x wash buffer for each well. The plate was 
struck on fresh towels to remove residual solution in each well. Addition of 100µl 
detection antibody was followed by incubation for 1 hour at 37C. The wells were 
washed 4x with 200µl 1x wash buffer, followed by addition of 100µl HRP-linked 
secondary antibody and incubation for 30mins at 37C. Next, the wells were washed 
4x with 200µl 1x wash buffer before adding 100µ of TMB substrate and incubation 
for 10mins at 37C. Lastly, 100µl STOP solution was added to each well followed by 
gentle shaking for a few seconds. The absorbance is then read at 450nm using 




2.2.6 Kinase assay for Bad phosphorylation 
Cells harvested from 6 well plates were lysed followed by protein concentration 
quantification. A 2x ATP/substrate cocktail was prepared by adding 100µl of 10mM 
ATP from the kit to 1.25ml substrate peptide to obtain a final concentration of ATP = 
400µM and substrate = 3µM. The 10x kinase buffer (250mM Tris HCl pH 7.5, 
100mM MgCl2, 1mM Na3VO4, 50mM β-glycerophosphate, 20mM DTT) was diluted 
with dH2O to obtain 2.5ml of 4x reaction buffer. Next, 1.2ml of 4x reaction buffer 
was transferred to each enzyme tube to obtain a 4x reaction cocktail (enzyme 
concentration = 4ng/µl). To 25µg of sample, 12.5µl of reaction cocktail was added 
and incubated for 5mins at room temperature. This was followed by the addition of 
25µl of 2x ATP/substrate cocktail to 25µl/well preincubated reaction 
cocktail/compound (25mM Tris-HCl (pH 7.5), 10mM MgCl2, 0.1mM Na3VO4, 5mM 
β-glycerophosphate, 2mM DTT, 200µM ATP, 1.5µM peptide, 50ng kinase) and 
incubation at room temperature for 30mins. To stop the reaction, Stop buffer (50mM 
EDTA, pH 8) was added. For each reaction, 25µl was transferred to a 96-well 
streptavidin-coated plate (Nunc, Rochester, NY, USA) containing 75µl dH2O 
followed by incubation at room temperature for 60mins. Each sample was then 
washed 3x with 200µl PBS/T (1x PBS, Tween-20). The phospho-Bad (ser112) 
antibody diluted in 1% BSA PBS/T was then added to each well in volumes of 100µl 
and incubated at room temperature for 120mins. The samples were washed 3x with 
200µl PBS/T followed by incubation with peroxidase-conjugated secondary antibody 
for 30mins. Following three washes with PBS/T, the substrate (3,3,5,5-




reaction was stopped by the addition of 2N HCl and the absorbance was measured at 
450nm using Spectrofluor-Plus spectrofluorometer (Tecan, GmbH, Grodig, Austria). 
 
2.2.7 Mitochondrial subcellular fractionation 
For each treatment, cells from 2x 100mm dishes were used. The cells were harvested 
and washed once with PBS, followed by lysis using 500µl extraction buffer A 
(200mM mannitol, 68mM sucrose, 50mM PIPES ph 7.4, 50mM KCl, 5mM EGTA, 
2mM MgCl2, 1mM DTT) supplemented with 1mg/ml leupeptin, 1mg/ml pepstatin, 
1mg/ml aproptinin and 1mM PMSF for 20mins on ice. The cells were then 
homogenized using a Dounce homogenizer, using 35 strokes for each sample. 
Thereafter, cell debris was removed by centrifugation at 700g for 10mins at 4C. The 
mitochondria fraction was then separated from the cytosolic fraction by centrifugation 
at 10 000g for 30mins at 4C. The pellet obtained (mitochondria fraction) was washed 
once with 500µl extraction buffer A by centrifugation at 10 000g for 10mins at 4C. 
The supernatant was centrifuged at 16 000g for 10mins at 4C to obtain the cytosolic 
fraction (supernatant). Both fractions were lysed using 0.5% Triton-X and left on ice 
for 15mins before storage in -80C. The fractions were then analyzed by Western 
blotting. 
 
2.2.8 SDS-PAGE and Western blotting 
Whole cell lysates were prepared by lysing the cells with RIPA Lysis buffer 




Triton X-100, supplemented with 1mM Na3VO4, 1mg/ml leupeptin, 1mg/ml 
pepstatin, 1mg/ml aproptinin and 1mM PMSF. Protein lysates were kept in - 80°C 
storage overnight. After clearing the lysate of cell debris by centrifugation at 10 
000rpm, protein concentration was determined for each sample and equal amounts of 
protein were aliquoted. Samples were denatured by boiling with 5x SDS buffer 
(0.313M Tris-HCl, pH 6.8, 10% SDS, 10% glycerol, 0.05% bromophenol blue, 0.5 M 
DTT) for 5mins before being resolved by 8%, 10% or 12% SDS-PAGE on the Bio-
Rad Mini PROTEAN 3 Cell system (Hercules, CA, USA), depending on the protein 
of interest. Typically, 30 μg of protein were loaded into each well. Kaleidoscope pre-
stained standards and biotinylated protein markers (Bio-Rad Laboratories, Hercules, 
CA, USA) were used as protein standards. Next, a nitrocellulose membrane (Pall 
Corporation, Ann Arbor, MI, USA) was used to transfer proteins from each gel and 
blocked for 1 hour at room temperature with 5% (w/v) non-fat milk in Tris-buffered 
saline with 0.1% (v/v) Tween-20 (TBST). Membranes were washed for 5mins three 
times with TBST and incubated overnight, at 4ºC with gentle agitation with primary 
antibody diluted to optimum concentration with 5% bovine serum albumin (BSA) in 
TBST. Following three 5min washes with TBST to remove unbound antibodies, the 
membranes were incubated with horseradish peroxidase (HRP) conjugated secondary 
antibody diluted with 5% non-fat milk in TBST for 1 hour at room temperature with 
gentle shaking. The membranes were washed three times to remove excess antibody 
and protein bands were detected by using the Supersignal West Pico 
Chemiluminescence 78 Substrate (Pierce, Rockford, IL, USA). In some experiments 
involving detection of phosphorylated proteins, blots were stripped with Restore 
Western Blot Stripping Buffer (Pierce, Rockford, IL, USA), and re-probed with total 




was quantified in some cases using the Analytical Imaging System (AIS) software 
(Imaging Research Inc., Ontario, Canada). 
 
2.2.9 Gene knockdown by RNA interference 
Transient transfections for LNCaP cells were achieved using Lipofectamine. Briefly, 
0.25 x 10
6
 cells were plated on 6-well plates 48 hours before transfection to achieve 
50% confluency at the time of transfection. On the day of transfection, the cells were 
washed once with PBS and 2ml of serum free RPMI media was added to each well. 
For each sample, the appropriate amount of siRNA and Lipofectamine was diluted 
separately in 100μl of Opti-MEM. The two diluted solutions were then combined to 
yield a combined solution of 200μl, followed by gentle shaking and incubation at 
20mins at room temperature to allow siRNA:Lipofectamine complexes to form. 
Thereafter, 200μl of the transfection solution was added dropwise into each well and 
incubated in a 37ºC, 5% CO2 incubator for 48 hours. The transfected cells were ready 
for subsequent assays and lysates were collected for Western blot analysis to 
determine transfection efficiency. The siRNAs used in this study were against Bad, 
Bax, Bak, Bcl-xL, NHE-1, NHE-2 and Pim-1. A control siRNA (non-homologous to 
any known gene; Qiagen, Xeragon) was used as the negative control, and the NHE-2 
siRNA was from Santa Cruz (Santa Cruz, California, USA).  The sequences of 






Akt 5`-AAUGCCCUUCUACAACCAGGA-dTdT Qiagen-Xeragon, CA, USA 
Bad 5`-AAGAAGGGACUUCCUCGCCCG-dTdT Proligo, Boulder, CO, USA 
Bak 5`-UGAGUACUUCACCAAGAUU-dTdT Qiagen-Xeragon, CA, USA 
Bax 5`-AAGGUGCCGGAACUGAUCAGA-dTdT Qiagen-Xeragon, CA, USA 
Bcl-xL 5`-CAGGGACAGCAUAUCAGAG-dTdT 1st Base, Singapore 
NHE-1 5`-AAGAUAGGUUUCCAUGUGAUC-dTdT Qiagen-Xeragon, CA, USA 
Pim-1 5`-GAUGGGACCCGAGUGUAUA-dTdT Dharmacon, Colorado, USA 
 
2.2.10 Measurement of intracellular H2O2 level 
Redox sensitive dye, 5-(and-6)-chloromethyl-2’,7’-dichlorofluorescin diacetate (CM-
H2DCFDA), was used to determine intracellular H2O2 concentration. Cells were 
washed once with PBS, trypsinized and centrifuged at 5,000rpm for 2mins. The pellet 
was resuspended with 5μM CM-H2DCFDA diluted in serum free media. After 30min 
incubation at 37C, the cells were spun down at 5,000rpm for 2mins, washed once 
with PBS and resuspended in PBS. Analysis by BD FACSCanto II flow cytometer 
(BD Biosciences, San Jose, CA, USA) of 10,000 events was performed using an 
excitation wavelength of 488nm. 
 
2.2.11 Measurement of intracellular O2
˙ˉ
 level 
A lucigenin-enhanced chemiluminescence assay was used for detection of 
intracellular O2
˙ˉ
 levels. The cells were first washed with 1ml PBS, trypsinized with 
200μl trypsin/EDTA, collected by adding 500μl complete media and centrifuged at 




ATP releasing reagent. Lucigenin solution of 10mM was prepared by dissolving the 
solid form in water. This was then injected automatically (100μl) into 400μl of the 
sample and its chemiluminescence was monitored over 60s using Sirius Luminometer 
(Berthold, Pforzheim, Germany). The remaining cell lysate was used to quantify the 
protein concentration, which was used to normalize the chemiluminescence level, 
expressed as relative unit (RFU) per μg of protein. The highest RFU per μg protein 
was taken as the intracellular O2
˙ˉ
 level for the particular treatment. 
 
2.2.12 Protein concentration determination 
Protein concentration was determined by using the Coomassie blue dye (Pierce 
Biotechnology, Rockford, IL, USA) for the lucigenin assay and caspase assays. 
Protein standards were prepared using bovine serum albumin and 5μl and 3μl of 
lysate was used for the lucigenin and caspase assay respectively. The lysates were 
incubated with 300μl Coomassie blue dye in a 96-well transparent flat bottom 
microtitre plate (Nunc, Rochester, NY, USA) for 5min before measuring the 
absorbance at 595nm using Spectrofluor-Plus spectrofluorometer (Tecan, GmbH, 
Grodig, Austria). 
 
2.2.13 Propidium iodide staining for DNA fragmentation 
Cells were harvested by scrapping them off the wells and spinning them down by 
centrifugation at 2500rpm for 5mins at 4C. They were then washed once with cold 




spun down at 10,000rpm for 5mins at 4C, washed once with PBS/1% FBS followed 
by resuspension in propidium iodide (PI) (10μg/ml) solution. RNAse A (0.25mg/ml) 
was also included in the PI solution to degrade any double stranded RNA which might 
bind to PI, causing poor resolution. The cells were then incubated in the dark for 
30min at 37C and stored at 4C until they were analyzed using the Coulter Epics 
Elite ESP Flow Cytometer (FL, USA). 15,000 events were analyzed using excitation 
and emission settings of 488nm and 610nm respectively. The cell cycle profiles were 
then analyzed using WinMDI Version 2.8 software to obtain the percentage of cells 
with sub-diploid DNA/sub G-1 phase. 
 
2.2.14 RNA isolation and PCR 
Total RNA was extracted with the Trizol reagent by washing cells once with PBS 
before adding 1ml of Trizol to each well of 6-well plates. The cells were lysed 
directly by pipetting up and down several times. The lysate was then transferred to 
microfuge tubes and stored at -80C. To isolate total RNA, 200µl of chloroform was 
added to each tube, followed by vigorous shaking by hand for 15s. The samples were 
left to incubate at room temperature for 2-3mins before centrifugation at 12 000g for 
15mins at 4C. Next, the aqueous phase is extracted and 500µl 100% isopropanol was 
added, followed by incubation at room temperature for 10mins. Centrifugation at 12 
000g for 10mins at 4C yields an RNA pellet which is washed with 1ml of 75% 
ethanol. The RNA pellet is then allowed to air dry before resuspension with 50-70µl 
RNAse-free water and incubated in a heat block at 55C for 10mins. Following 




Transcription Reagent (Applied Biosystems) following the manufacturer’s 
description. The cDNA is then amplified using the Platinum Taq DNA Polymerase 
(Invitrogen, Carlsbad, CA, USA), using the appropriate primers and annealing 





Forward     5`- TCGAAGCTCAGAGCCACCACGA 
Reverse     5`- GTGCGCACGTGTGTGTAGTCGA 
60C 
NHE-2 
Forward     5`- TCCGATGCTGTTGCTGCTGC 
Reverse     5`- TGTCGCTGAGGCCGAATGCTT 
59C 
NHE-3 
Forward     5`- ACACTGACGCCCACCGTCTTCT 
Reverse     5`- AACCACGGTGACTGCGTCGTT 
59C 
β-actin 
Forward     5`-AGAGCCTCGCCTTTGCCGAT 
Reverse     5`-AGGGCGACGTAGCACAGCTT 
58C 
 
Lastly, the samples were analyzed on a 2% agarose gel loaded with a 1kbp marker. 
 
 
2.2.15 Statistical analysis 
Results were computed as mean ± SE. Statistical analysis was performed using 
algorithm of unpaired Student’s t-test from Microsoft Excel software (Redmond, WA, 
USA) to compare the means of relevant experimental conditions. Probability values of 




CHAPTER 3: RESULTS 
3.1 MECHANISM OF LY294002 INDUCED APOPTOSIS 
 The importance of the PI3K-Akt pathway in LNCaP has been established by 
findings demonstrating the death inducing effects of LY294002 in shutting down this 
pathway (Carson et al., 1999; Yang et al., 2003, Chao and Clement, 2006). Also, the 
ability of LNCaP cells to circumvent the death inducing effects of LY294002 suggests 
that there may be other survival pathways preventing apoptosis in LNCaP. Several 
groups have attempted to understand the molecular basis for LNCaP survival, as 
covered in the introduction earlier (Figure 8). However, several key questions remain 
unanswered; this report will attempt to define the parameters required for inducing 
apoptosis and investigate if O2˙ˉ plays a role in participating and/or regulating these 
parameters.  
 Previous work on the LNCaP model has identified the involvement of Bcl-xL 
in enhancing survival by overexpression (Yang et al., 2003; Sun et al., 2008). 
Similarly, the BH3-only protein, Bad, was also shown to be phosphorylated by RSK1 
via the MAPK/ERK pathway (Chao and Clément, 2006). Recently, our group also 
showed that the synthetic androgen, R1881, is able to activate AR and induce an 
increase in Bcl-xL expression, promoting the effective sequestration of Bak in LNCaP 
cells (Kumar et al., 2011). In addition, the sequestration was further enhanced by the 
phosphorylation of Bad, resulting in the effective prevention of apoptosis. These 
results suggest that Bad and Bcl-xL are key players in the regulation of apoptosis in 
LNCaP. Given the overlapping and similar functions of Bax and Bak, the following 




1. Bad dephosphorylation, specifically ser75 
2. Bcl-xL overexpression 
3. Bax/Bak translocation and activation 
The defined parameters will then be assessed in LNCaP survival induced by serum. In 
addition, the involvement of O2˙ˉ in the death circuitry will also be looked into. 
 
3.1.1 Bad dephosphorylation is essential for apoptosis 
To establish the importance of Bad, LNCaP cells were subjected to Bad 
knockdown by RNA interference for 48 hours before treatment with LY294002 for a 
further 24 hours. The cells were then harvested and lysed, and the lysates assessed for 
caspase 3 activity, normalized over protein concentration in the lysates. Cells were 
also harvested and fixed for cell cycle analysis. A Western blot analysis was carried 
out to ascertain the silencing of Bad (Figure 9A). Figure 9B shows that cells 
transfected with control siRNA had a very low percentage in sub-G1 phase, but this 
increased dramatically upon treatment with LY294002. In comparison, a smaller 
percentage of cells transfected with Bad siRNA and treated with LY294002 were in 
sub-G1 phase. The profiles of the cell cycles used in this experiment can be seen in 
Figure 9C. Figure 9D shows that cells transfected with control siRNA showed low 
levels of caspase 3 activity, and upon treatment with LY294002, caspase activity was 
increased significantly. Also, the down regulation of Bad expression by Bad siRNA 
did not result in an increase in caspase 3 activity. Upon treatment with LY294002, 




to cells transfected with control siRNA. The lack of killing in the absence of Bad 










Figure 9: Role of Bad in LY294002 induced cell death 
LNCaP cells were transfected with siRNA specific for Bad and control siRNA for 48 hours 
before treatment. (A) A Western blot analysis of the lysates 48 hours following transfection 
shows the level of Bad silencing. (B) Transfected cells were treated with 25µM LY294002 in 
the absence of serum (NS+LY) for 24 hours, followed by cell cycle profiling. The control was 
cells grown in fresh serum free media for 24 hours. Results shown are mean ± S.E. of two 
independent experiments done in duplicates. (C) Cell cycle profiles of the treatments showing 
the percentage of cells in various stages of the cell cycle. M1: sub-G1 phase, M2: G1 phase, 
M3: S phase, M4: G2/M phase. (D) Transfected cells were treated with LY294002 (NS+LY) 
for 6, 12 and 24 hours and harvested. The cells were then lysed, and the lysates assessed for 
caspase 3 activity normalized over protein concentration in the lysates. Results shown are 











3.1.2 Bax is required for LY294002 induced apoptosis 
The pro-apoptotic protein Bax plays a major role in the execution of the 
intrinsic apoptotic pathway. Bax has been shown to be a vital component required for 
cell death in many cancers including prostate cancer. Hence, it is important to 
ascertain the role of Bax in the regulation of the apoptotic program in LNCaP. To 
investigate if Bax is involved in LY294002 induced apoptosis, LNCaP cells were 
treated with LY294002 in the absence of serum for 24 hours, after which they were 
harvested. The cells were then lysed and fractionated into the mitochondria and 
cytosolic fraction. The fractions were then analysed using Western blotting to 
determine the location of Bax following LY294002 treatment. Bax was detected in 
both the mitochondria and cytosolic fractions, but was present in higher amounts in 
the mitochondria fraction of cells treated with LY294002 as compared to the 
untreated control (Figure 10A). In line with recent findings by Edlich et al., presence 
of Bax in the mitochondria of healthy cells is normal; Bax localization in the cell is in 
a constant state of flux, shuttling to and from the mitochondria (Edlich et al., 2011). It 
is upon the treatment with LY294002 that the equilibrium of Bax localization is 
shifted towards the mitochondria, indicating that increased and irreversible Bax 
translocation to the mitochondria was a key event in LY294002 induced apoptosis. 
The translocation of Bax to the mitochondria alone is insufficient to initiate 
apoptosis; the activation of Bax on the mitochondria is essential in the function of 
apoptosis. Detection of Bax activation was achieved by using a mouse antibody that 
recognizes the N-terminus of the Bax protein (anti-Bax6A7) which is exposed upon 
Bax activation. LNCaP cells were treated with LY294002 for 12 and 24 hours in the 




were permeabilized, allowing the bulky antibody to enter the cells to bind to activated 
Bax proteins. Following an overnight incubation, the cells were permeabilized again 
to allow secondary antibodies with conjugated FITC to enter. These antibodies which 
are specific for mice antigens only recognize and bind to the Bax antibodies, 
providing a means to quantify the amount of Bax present in cells. The cells were then 
analyzed for FITC fluorescence using a flow cytometer, and the profiles obtained 
were analyzed using WINMDI 2.8 to determine the percentage of activated Bax in 
each sample. Figure 10B shows that the treatment of Bax with LY294002 resulted in 
an increase in Bax activation. The low percentage of Bax activation in untreated 
control cells also indicate that Bax found on the mitochondria of untreated cells were 
not activated. 
LNCaP cells were grown and transfected with control and Bax siRNA for 48 
hours before being subjected to LY294002 treatment. Cells were harvested for cell 
cycle analysis and lysates collected for caspase 3 activity assay. A Western blot 
analysis was carried out to ascertain the silencing of Bax (Figure 11A). Figure 11B 
shows that a very low percentage of cells transfected with control siRNA were in sub-
G1 phase, and a high percentage were in sub-G1 phase upon treatment with 
LY294002. Cells transfected with Bax siRNA had a lowered percentage in sub-G1 
phase upon LY294002 treatment. The profiles of the cell cycles can also be seen in 
Figure 11C.  Figure 11D shows that cells transfected with control siRNA and treated 
with LY294002 resulted in low and high caspase 3 activity respectively. Similar to 
Bad, the knockdown of Bax resulted in a lowered caspase 3 activity, illustrating that 






Figure 10: LY294002 treatment results in increased Bax translocation and activation 
(A) LNCaP cells grown in serum free media treated with LY294002 for 24 hours were 
harvested and lysed. The lysates were subjected to sub cellular fractionation to obtain an 
insoluble mitochondria fraction and a soluble cytosolic fraction. The fractions were then 
subjected to a Western blot analysis, with VDAC and SOD1 as the mitochondria (m) and 
cytosolic (c) fraction markers respectively to assess fraction purity. The gel shown is 
representative of three independent experiments. (B) Serum starved LNCaP cells were 
subjected to 25µM LY294002 treatment in the absence of serum (NS+LY) for 12 and 24 
hours. The cells were harvested and fixed, followed by permeabilization and incubation with 
anti-Bax6A7 primary antibodies overnight. This was followed by incubation with secondary 
FITC conjugated antibodies. The percentage activated Bax was determined by analzying the 
profiles on WINMDI 2.8. The data presented represents the mean of three independent 









Figure 11: Bax is required in LY294002 induced cell death 
LNCaP cells were transfected with siRNA specific for Bax and control siRNA for 48 hours 
before treatment. (A) A Western blot analysis of the lysates 48 hours following transfection 
shows the level of Bax silencing. (B) Transfected cells were treated with 25µM LY294002 in 
the absence of serum (NS+LY) for 24 hours, followed by cell cycle profiling. The control was 
cells grown in fresh serum free media for 24 hours. Results shown are mean ± S.E. of two 
independent experiments done in duplicates. (C) Cell cycle profiles of the treatments showing 
the percentage of cells in various stages of the cell cycle. M1: sub-G1 phase, M2: G1 phase, 
M3: S phase, M4: G2/M phase. (D) Transfected cells were treated with LY294002 (NS+LY) 
for 6, 12 and 24 hours and harvested. The cells were then lysed, and the lysates assessed for 
caspase 3 activity normalized over protein concentration in the lysates. Results shown are 












3.1.3 Bak activation is required for apoptosis 
Bak, another well known pro-apoptotic Bcl-2 protein, is known to perform 
similar functions with Bax. The single knockdown of Bad and Bax under LY294002 
treatment still yielded decent amounts of caspase 3 activity, indicating the presence of 
other pro-apoptotic proteins performing redundant functions. Our group has shown 
recently that Bak exhibits strong interaction with Bcl-xL (Kumar et al., 2011), 
highlighting the important role of Bak as the effector for caspase activation. We had 
also demonstrated that silencing of Bak in LNCaP resulted in lowered caspase 3 
activity in response to LY294002 treatment (Figure 12B). Furthermore, we also 
showed that LY294002 treatment resulted in an increase in the percentage of activated 
Bak (Figure 12A). Bak silencing was more effective in preventing LY294002 induced 
increase in caspase 3 activity than Bax, indicating that Bak is more effective in 
inducing apoptosis as compared to Bax. Indeed, we have shown that the synthetic 
androgen, R1881 prevents the activation of Bak but not Bax, demonstrating the key 
role of Bak in determining LNCaP cell fate (Kumar et al., 2011). 
To further illustrate the importance of both Bax and Bak in the execution of 
apoptosis in LNCaP, both Bax and Bak were silenced using gene-specific siRNA. 
LNCaP cells were grown and transfected with control, Bax and Bak siRNA for 48 
hours before being subjected to LY294002 treatment. The cells were harvested for 
cell cycle analysis and Western blotting. The efficiency of the silencing was shown 
via Western blot (Figure 12C). The cell cycle profiles (Figure 12E) show that upon 
treatment with LY294002, there was a higher percentage of cells in sub-G1 phase for 
cells transfected with control siRNA as compared to those transfected with Bax and 




response to LY294002 treatment in the absence of Bax and Bak is an indication that 










Figure 12: Bax and Bak are involved in LY294002 induced apoptosis 
(A) LNCaP cells were serum starved before treatment with 25µM LY294002 in the absence 
of serum for 9 and 24 hours. The cells were then assessed for Bak activation. Results shown 
are the mean ± S.E. of three independent experiments done in duplicates.  (B) LNCaP cells 
were transfected with siRNA specific for Bak and control siRNA for 48 hours before 
treatment. A Western blot analysis of the lysates 48 hours following transfection shows the 
level of Bak silencing. The lysates were assessed for caspase 3 activty at 3 and 6 hours. 
Results shown are mean ± S.E. of three independent experiments done in duplicates. (C) 
LNCaP cells were transfected with siRNA specific for Bax, Bak and control siRNA for 48 
hours before treatment. A Western blot analysis of the lysates 48 hours following transfection 
shows the level of Bax and Bak silencing. (D) Transfected cells were treated with 25µM 
LY294002 in the absence of serum (NS+LY) for 24 hours, followed by cell cycle profiling. 
The control was cells grown in fresh serum free media for 24 hours. Results shown are the 
mean ± S.E. of two independent experiments done in duplicates. (E) Cell cycle profiles of the 
treatments showing the percentage of cells in various stages of the cell cycle. M1: sub-G1 

















3.1.4 Bcl-xL downregulation is required for apoptosis 
The importance of Bcl-xL in promoting LNCaP survival had been 
demonstrated in previous studies. Serum and synthetic androgen R1881 were shown 
to be able to increase Bcl-xL expression, resulting in enhanced survival and resistance 
to LY294002 induced apoptosis in LNCaP (Yang et al., 2003; Sun et al., 2008). Bcl-
xL plays an important role in survival by sequestering Bak and preventing Bax/Bak 
oligomerization and MOMP (Willis and Adams, 2005). Indeed, our group had 
recently shown that R1881 inhibits LY294002 induced apoptosis by increasing Bcl-
xL expression (Kumar et al., 2011). In fact, the silencing of Bcl-xL led to an increase 
in caspase 3 activity in untreated control cells (Figure 13A). The protective effect of 
R1881 against LY294002 induced apoptosis can also be circumvented by Bcl-xL 













Figure 13: Bcl-xL downregulation is required for LY294002 induced apoptosis 
(A) LNCaP cells were treansfected with control (control siRNA) or Bcl-xL (Bcl-xL siRNA) 
siRNA for 48 hours. The cells were then serum deprived followed by an incubation in the 
presence or absence of 5nM R1881 for 24 hours in phenol red free RPMI before being treated 
with 25µM LY294002 for 3-24 hours. (B) Efficiency of Bcl-xL silencing by siRNA was 





The results shown in this section highlight the importance of the various 
members of the Bcl-2 family proteins. In particular, Bad, Bax, Bak and Bcl-xL were 
shown to be key to the apoptotic program. Efficient killing of LNCaP cells require 
both Bax and Bak activation of sufficient magnitude that would allow MOMP. This 
can be achieved by dephosphorylation of Bad and the downregulation of Bcl-xL, 
which results in the disruption of Bcl-xL sequestration of Bak, allowing the activated 
Bak to form oligomers with Bax. Similarly, enhanced Bax activation would also result 
in their increased availability for oligomerization with Bak. LY294002, apart from 
inhibiting PI3K, is also able to induce Bad dephosphorylation and increase Bax 
translocation to the mitochondria, resulting in a net increase in both Bax and Bak 
activation, thus allowing for efficient cell death (Figure 14). 
The four members of the Bcl-2 family, Bad, Bcl-xL, Bax and Bak have been 
shown to be key players in defining cell fate in LNCaP cells. The regulation of these 
four players defines the parameters determining LNCaP survival. Previous findings 
highlighting the role of EGF and R1881 in promoting LNCaP survival can be 
explained by this model; the phosphorylation of Bad by RSK1 and Pim-1 prevents 
cell death by reducing the interruption of the interaction between Bcl-xL and Bak in 
LNCaP cells. In addition, R1881 enhances Bcl-xL expression, increasing the cell’s 
capacity to sequester Bak more effectively. The parameters defined in this section will 
be used subsequently to assess the mechanism and efficiency of serum and oxidative 







Figure 14: Mechanism of LY294002 induced apoptosis 
Apoptosis in LNCaP requires both activated Bak and Bax for oligomerization which leads to 
cytochrome c release. Bak is prevented from interacting with Bax by Bcl-xL, which can be 
sequestered by dephosphorylated Bad. Bax, upon activation, is available for interaction with 
Bak to bring about apoptosis. The currently known PI3K-Akt independent survival pathways 
in LNCaP prevents apoptosis by maintaining Bad phosphorylation and/or increasing Bcl-xL 
expression. These have the overall effect of making Bak unavailable for oligomerization. 
EGF and R1881 maintains Bad phosphorylation, resulting in its inability to disrupt  
interactions between Bcl-xL and Bak, preventing apoptosis. Serum can increase Bcl-xL 










3.2 SERUM PREVENTS LY294002 INDUCED APOPTOSIS 
While EGF and R1881 prevents apoptosis in LNCaP cells in a clear defined 
manner, the mechanism of serum enhanced survival is not well defined, despite its 
much earlier discovery (Carson et al., 1999). Serum contains extracellular growth 
factors and mitogens that can induce cell proliferation and promote survival. In 
normal eukaryotic cells, serum provides the constant extracellular growth signaling 
that promotes proliferation and ensure their survival. Unsurprisingly, the withdrawal 
of serum in normal non-carcinogenic cells translates to a lack of proliferation as well 
as the triggering of apoptosis.  
In contrast to normal non-carcinogenic cells, LNCaP cells survive regardless 
of the absence or presence of growth factors, by virtue of its constitutively active 
PI3K-Akt survival pathway (Tang et al., 1998). The addition of PI3K inhibitors like 
Wortmannin or LY294002 in the absence of serum causes LNCaP cells to undergo 
apoptosis (Lin et al., 1999), which can be prevented by the presence of serum (Carson 
et al., 1999; Chao and Clément, 2006). LNCaP cells treated with LY294002 in the 
absence of serum are stressed and many floating cells can be seen (Figure 15A). The 
addition of serum to LY treated cells rescues them from the stress, such that they 
revert to looking like cells grown in untreated condition. The protective effect of 
serum is independent of Akt phosphorylation, as LNCaP cells treated with LY for 
30min and 60min had dephosphorylated Akt at ser473, regardless of presence of 






Figure 15: Serum prevents LY294002 induced apoptosis 
(A) LNCaP cells were serum deprived for 24 hours before treatment with LY294002 in the 
presence (S+LY) or absence of serum (NS+LY) for 24 hours. Control cells were given fresh 
growth media with (S) or without serum (NS).  Photographs showing the cell morphology 
were taken at 10x magnification. (B) LNCaP cells serum deprived for 24 hours were treated 
with LY294002 for 30-60min, after which they were harvested and lysed. The lysates were 
then analyzed for Akt phosphorylation at serine 473 using Western blotting. The gel shown is 





Serum deprived LNCaP cells were treated with LY294002 with or without 
serum for 2, 4, 12 and 24 hours prior to harvesting for caspase assay. The protective 
effect of serum against LY-induced cell death in LNCaP cells could be seen when 
serum reduced the percentage of cells in sub-G1 phase in LY treated cells (Figure 
16A) from 25% to 7%. Similarly, caspase 3 and 9 activity was lowered when LY 
treated cells (NS+LY) were supplemented with serum (S+LY) (Figure 16C and 16D). 
This suggests that serum is able to override the death inducing effects of LY294002 
by an Akt-independent pathway. The mechanism of serum induced protection against 























Figure 16: Serum rescues LY294002 induced cell death in LNCaP cells 
(A) LNCaP cells were serum starved for 24 hours before treatment with LY294002 in the 
presence or absence of serum for a further 24 hours. The cells were then harvested and fixed 
for propidium iodide (PI) staining. The percentage of cells in sub-G1 phase was derived by 
analyzing the cell cycle profiles on a flow cytometer. Results shown are the mean of three 
independent experiments done in duplicates ± S.E. (B) Cell cycle profiles of the above 
treatment. M1: sub-G1 phase, M2: G1 phase, M3: S phase, M4: G2/M phase. (C) LNCaP 
cells were treated with LY294002 for 2-24 hours following 24 hours of serum deprivation. 
The cells were then harvested and lysed, and lysates were assessed for caspase 3 activity 
normalized over protein concentration in the lysates. Results shown are the mean ± S.E. of 
three independent experiments done in duplicates. (D) LNCaP cells were treated with 
LY294002 with or without serum for 2-24 hours following 24 hours of serum deprivation. 
The cells were then harvested and lysed, and lysates were assessed for caspase 9 activity 
normalized over protein concentration in the lysates. Results shown are the mean ± S.E. of 




3.2.1 Serum promotes overexpression of Bcl-xL 
LNCaP cells were grown in media with or without serum for 24 hours before 
harvesting for Western blot analysis. Figure 17A showed that cells grown in serum 
starved media had lower levels of Bcl-xL expression as compared to cells grown with 
serum. A densitometric analysis was performed on two separate Western blots (Figure 
17B). This was consistent with findings that attribute the pro-survival effect of serum 
to Bcl-xL overexpression (Yang et al., 2003; Sun et al., 2008). Recently, evidence 
suggests that Bcl-xL is not only involved in the sequestration of Bak, but also 
responsible for the retrotranslocation of Bax from the mitochondria to the cytosol 
(Soriano and Scorrano, 2011). In view of this, the increased expression of Bcl-xL by 
serum has an additive affect on cell survival, playing an important role in increasing 













Figure 17: Serum can increase Bcl-xL expression 
(A) LNCaP cells were grown in media with (S) or without serum (NS) for 24 hours before 
harvesting for Western blot analysis. The gel presented is a representation of two independent 
blots. (B) A densitometric analysis was performed on the 2 sets of Western blots. The 
intensity of Bcl-xL bands were normalized over the loading control. The result shown is the 









3.2.2 Serum maintains Bad phosphorylation 
In the previous section, the framework of the apoptotic program induced by 
LY294002 was established. Bad dephosphorylation is an important step in permitting 
Bak function. To determine if the protective effects of serum against LY294002 
induced apoptosis is Bad dependent, LNCaP cells were incubated in media with or 
without serum for 1 hour before harvesting for Western blot analysis. Prior to the 1 
hour incubation, the cells were either subjected to serum deprivation for 24 hours or 
left to grow in normal serum supplemented media. Figure 18A shows that cells 
exposed to an hour of serum incubation had higher levels of Bad phosphorylation as 
compared to cells grown in media without serum. A densitometric analysis on 3 
independent blots was performed (Figure 18B), showing that the absence of serum led 
to a decrease in Bad phosphorylation. However, serum had no effect on Bad 
phosphorylation in the absence of serum deprivation. This indicates that serum 
deprivation was required to lower Bad phosphorylation that could be restored 
following exposure to serum. Therefore, it is logical to conclude that serum can 






Figure 18: Serum maintains Bad phosphorylation 
(A) LNCaP cells were subjected to either 24 hour serum deprivation or grown in normal 10% 
FBS supplemented medium, followed by replacing the media with fresh serum free media 
(NS) or media supplemented with 10% FBS (S) for one hour. The cells were subsequently 
harvested and lysed, followed by Western blot analysis to determine the amount of Bad 
phosphorylation. The gel is a representation of 3 independent experiments. (B) A 
densitometric analysis was performed on the 3 sets of Western blots. The intensity of the 
phosphorylated Bad was normalized over the corresponding total Bad detected. The result 






3.2.3 Serum prevents Bax activation and translocation induced by LY294002 
The activation and translocation of Bax is vital in the function of apoptosis 
upon LY294002 insult. Detection of Bax activation was achieved by using a mouse 
antibody that recognizes the N-terminus of the Bax protein (anti-Bax6A7). LNCaP 
cells were treated with LY294002 for 12 and 24 hours in the presence and absence of 
serum, followed by harvesting and fixation. The fixed cells were permeabilized, 
allowing the bulky antibody to enter the cells to bind to activated Bax proteins. 
Following an overnight incubation, the cells were permeabilized again to allow 
secondary antibodies with conjugated FITC to enter. The cells were then analyzed for 
FITC fluorescence using a flow cytometer, and cell profiles obtained were analyzed 
for Bax activation using WINMDI 2.8. LNCaP cells treated with LY294002 for 24 
hours were also harvested and fractionated for Western blot analysis. 
Cells treated with LY294002 in the absence of serum had more Bax 
translocation from the cytosol to the mitochondria, as the Western blot from Figure 
19A shows a decrease in the amount of Bax in the cytosolic fraction as well as a 
corresponding increase in the amount of Bax in the mitochondria fraction as 
compared to the untreated control. In contrast, LY294002 treatment in the presence of 
serum (S+LY) had more Bax in the cytosolic fraction as compared to treatment in the 
absence of serum (NS+LY). This suggests that LY294002 induced translocation of 
Bax from the cytosol to the mitochondria can be prevented by serum. Presence of Bax 
in the mitochondria fractions of untreated cells is not cytotoxic, as Bax 
retrotranslocation from the mitochondria to the cytosol is constantly occurring under 
the influence of Bcl-xL (Soriano and Scorrano, 2011). In addition, the low percentage 




present in the mitochondria, they remain inactive and are unable to induce MOMP 
(Figure 19B). The role of serum in influencing Bax action is also evident in Bax 
activation; the addition of serum to LY294002 treatment resulted in a decrease in the 
percentage of Bax activation upon LY294002 treatment, implying that the increase in 
activated Bax can be prevented by serum (Figure 19B). Taken together, these results 
indicate that serum is able to block both Bax translocation and activation. 
In summary, serum is able to promote cell survival in LNCaP cells by 
maintaining Bad phosphorylation, upregulating Bcl-xL expression and preventing 
Bax and Bak activation (Figure 20). This is in line with the parameters for LNCaP 
survival defined in the previous chapter. The phosphorylation of Bad and upregulation 
of Bcl-xL resulted in the overall decrease in activated Bak, thus reducing its 
effectiveness in inducing MOMP and apoptosis. Furthermore, the prevention of Bax 
translocation from the cytosol to the mitochondria by serum also enhances survival by 
preventing an accumulation of Bax in the mitochondria. The blocking of both Bax and 
Bak activation by serum leads to an overall decrease in MOMP and greatly enhances 









Figure 19: Serum prevents Bax activation and translocation induced by LY294002 
(A) LNCaP cells were treated with 25µM LY294002 for 24 hours before harvesting. The cells 
were  lysed, followed by sub cellular fractionation to obtain an insoluble mitochondria 
fraction and a soluble cytosolic fraction. The fractions were then subjected to a Western blot 
analysis, with VDAC and SOD1 as the mitochondria and cytosolic fraction markers 
respectively to assess fraction purity. The gel is representative of three independent 
experiments. (B) Serum starved LNCaP cells were subjected to 25µM LY294002 treatment in 
the presence (S+LY) or the absence of serum (NS+LY) for 12-24 hours. The cells were 
harvested and fixed, followed by permeabilization and incubation with anti-Bax6A7 primary 
antibodies overnight. This was followed by incubation with secondary FITC conjugated 
antibodies. The percentage activated Bax was measured as percentage cells with FITC 
fluorescence. Cells were treated with staurosporine to induce Bax activation for internal 
positive control. The data presented represents the mean of three independent experiments ± 






Figure 20: Serum prevents apoptosis in LNCaP cells 
Serum is able to maintain Bad phosphorylation, increase Bcl-xL expression and prevent Bax 
translocation and activation in LNCaP cells. This results in a decrease in activated Bak and 
Bax, thus preventing MOMP and apoptosis, providing protection against cell death induced 
by LY294002. Similarly, EGF and R1881 can prevent LY294002 induced cell death by 












3.3 SUPEROXIDE REGULATION OF CELL SURVIVAL 
As discussed previously, the alterations to normal cell metabolism and 
biosynthesis pathways in cancer cells often lead to increase in ROS production and 
oxidative stress. The high amounts of oxidative stress have been shown to be 
correlated with aggressiveness and enhanced survivability in cancer cells, more 
specifically on prostate cancer (DeWeese et al., 2001; Dakubo et al., 2006). These are 
strong evidence that suggest that ROS, O2˙ˉ in particular, plays a vital role in 
enhancing the survivability of prostate cancer cells. In addition, it has also been 
established in prostate cancer cell lines that the source of O2˙ˉ is from membrane 
bound NOX complexes that gives rise to cytosolic O2˙ˉ (Kumar et al., 2008). In this 
section, the effect of O2˙ˉ on Bad phosphorylation, Bcl-xL expression and Bax/Bak 
activation in LNCaP cells will be investigated. 
To investigate the roles of O2˙ˉ in LNCaP survival, DPI and DDC were used 
as tools to manipulate intracellular O2˙ˉ levels. DPI is an inhibitor of flavoprotein-
dependent NADPH oxidases (Benhar et al., 2001); it would inhibit the production of 
O2˙ˉ and result in an overall reduction in intracellular O2˙ˉ. DDC is a Cu
2+
 chelator, 
which sequesters the Cu
2+
 required to allosterically activate cytosolic SOD1, thus 
increasing intracellular O2˙ˉ levels. Lucigenin assay was used to detect intracellular 
O2
˙ˉ
 levels. Upon uptake, lucigenin is reduced to lucigenin cation radical, which then 
reacts with intracellular O2
˙ˉ
, forming an unstable dioxetene intermediate. The 
decomposition of this intermediate results in the formation of excited N-
methlyacridine, which emits a photon when it returns to ground state. DDC inhibits 
SOD1, leading to the buildup of O2
˙ˉ
. Upon DPI treatment, intracellular O2
˙ˉ




reduced compared to cells in serum (Figure 21A). Also, DDC treatment with DPI can 
negate the decrease in DPI induced O2
˙ˉ
 levels.  
While the use of DPI allows the reduction in O2˙ˉ levels, it is known that H2O2 
is produced when DPI is used. However, whilst DDC is able to reverse the effects of 
DPI by inhibiting O2˙ˉ dismutation, it is unable to remove H2O2. This was 
demonstrated by measuring the levels of H2O2 in the cell using flow cytometry. 
LNCaP cells treated with DPI and/or DDC were harvested after 1 hour incubation and 
washed with PBS. Subsequently, DCFDA dye was added to the cells where they are 
taken up and deacetylated by intracellular esterases to dichlorofluorescein (DCFH). 
DCFH is then able to react with ROS like H2O2 and OH˙ˉ radicals to form the 
fluorophore DCF (Halliwell and Gutteridge, 2007). The amount of H2O2 present in 
each cell is picked up using flow cytometry, by measuring the amount of 
fluorescence, giving an accurate indication of H2O2 produced by DPI and DDC. 
It can be seen that the use of DPI as well as LY resulted in an increase in H2O2 
levels (Figure 21B). DDC treatment did not result in a significant increase in H2O2, 
and DDC is unable to reverse the increase in H2O2 production by DPI treatment. H2O2 
is a ROS that is commonly involved in signaling, and is cytotoxic at high 
concentrations. It is thus possible that cell death observed from O2˙ˉ reduction due to 
DPI treatment could be attributed to H2O2 production. However, the above result 
demonstrates that since DDC is unable to reverse the production of H2O2 by DPI 
treatment, any death inducing effects DPI has on LNCaP cells that can be rescued by 






Figure 21: Decrease in superoxide can bypass serum protection 
(A) LNCaP cells were serum deprived for 24 hours before treatment with 6µM DPI and/or 
1mM DDC for 1-4 hours. Cells were then harvested for measurement of intraceulluar O2˙ˉ 
using lucigenin assay as described in Materials and Methods. (B) LNCaP cells serum 
deprived for 24 hours were treated with 25µuM LY294002, 6µM DPI and/or 1mM DDC for 
an hour. A positive control of 5mM H2O2 was used. The cells were then collected and 
measured for ROS production using DCFDA dye (G mean). ROS production is measured as 
the amount of FITC fluorescence detected. Results shown are mean ± S.E. of three 





3.3.1 Superoxide reduction results in loss of serum protection against LY294002 
induced apoptosis 
Serum deprived LNCaP cells were treated with LY294002, DPI and/or DDC 
with or without serum for 2, 4, 12 and 24 hours prior to harvesting for caspase assay. 
High caspase 3 (Figure 22A) and caspase 9 (Figure 22B) activity can be observed 
after 24 hours of treatment with LY in the absence of serum. The presence of serum is 
able to protect LNCaP cells from LY-induced caspase activity. The addition of DPI 
removed the protective effect of serum against LY-induced caspase 3 and 9 activity, 
but the effect of DPI can be countered by DDC. As it had been previously shown that 
DPI and DDC can decrease and increase O2˙ˉ levels respectively, these results suggest 
that O2˙ˉ plays an important role in maintaining the Akt-independent survival 
pathway. To ensure the non cytotoxic nature of DDC, a series of controls were done. 
DDC treatment alone did not result in high caspase 3 (Figure 22C) nor 9 (Figure 22D) 
activities. The synergistic use of DDC with DPI also did not result in high caspase 3 
and 9 activities. Furthermore, the combined treatment of DDC and LY did not yield 
high caspase activity, adding further weight to the hypothesis that the reduction of 
O2˙ˉ results in cell death. This was consistent with the percentage of cells in sub-G1 
phase obtained following similar treatments. The percentage was increased when 
LNCaP cells were treated synergistically with LY and DPI in the presence of serum 
(S+DPI+LY) as compared to LY treatment alone in serum (S+LY) (Figure 22E). 
However, the addition of DDC to DPI and LY treatment reduced the percentage of 
cells in sub-G1 phase, demonstrating that O2
˙ˉ
 was playing a role in mediating the 
Akt-independent survival pathway. Caspase activity assays showed that synergistic 




and 9 activity which corresponds to the level induced by LY treatment in the absence 
of serum (NS+LY) (Figure 22A and 22B). The addition of DDC (S+DPI+DDC+LY) 











Figure 22: Superoxide reduction results in loss of serum protection against LY294002 
induced apoptosis 
(A) LNCaP cells were serum deprived for 24 hours before treatment with 25µM LY294002, 
6µM DPI and/or 1mM DDC for 2-24 hours. The cells were then harvested and lysed, and 
lysates were assessed for caspase 3 activity normalized over protein concentration in the 
lysates. Results shown are mean ± S.E. of three independent experiments done in duplicates. 
(B) The same experimental procedure was repeated for the assessment of caspase 9 activity. 
Results shown are mean ± S.E. of three independent experiments done in duplicates. (C), (D) 
Controls were performed to ensure that DDC could not incduce high caspase 3 or 9 activity. 
(E) LNCaP cells were serum starved for 24 hours before treatment with 25µM LY294002, 
6µM DPI and/or 1mM DDC for 24 hours. The cells were then harvested and fixed for 
propidium iodide (PI) staining. The percentage of cells in sub-G1 phase was derived by 
analyzing the cell cycle profiles on a flow cytometer. Results shown are a mean of three 
independent experiments done in duplicates ± S.E. (F) Cell cycle profiles of the above 

















3.3.2 Serum and superoxide are distinct pathways 
Since O2˙ˉ can remove the protective effects of serum against LY294002 
induced apoptosis, it is possible that the pro-survival effects of serum are mediated by 
O2˙ˉ. Alternatively, O2˙ˉ and serum could be distinct pathways regulating the same 
target. To demonstrate if serum is upstream of O2˙ˉ, cells were serum starved for 24 
hours before adding:  
1. Fresh 10% serum media 
2. Fresh 0% serum media 
3.  Unchanged control 
The cells were harvested after 1, 2 and 4 hours and assayed for O2˙ˉ levels 
using the lucigenin assay as described in Materials and Methods. Figure 21A shows 
that regardless of serum, O2˙ˉ levels remained unchanged to the control, 
demonstrating that serum has no effect on O2˙ˉ levels. This implies that serum and 
O2˙ˉ promote survival possibly via similar targets, but via independent pathways of 
activation (Figure 23B). Since serum can promote LNCaP survival by influencing the 
3 parameters of apoptosis in LNCaP (Figure 20), it would be logical to question if 
O2˙ˉ mediated survival could be regulated by maintaining Bad phosphorylation, 









Figure 23: Superoxide and serum are distinct pathways 
(A) LNCaP cells were serum deprived for 24 hours before adding fresh 10% serum media (S), 
fresh 0% serum media (0%FBS) or left unchanged (serum deprived) for 1-4 hours. Cells were 
then harvested for measurement of intraceulluar O2˙ˉ using lucigenin assay as described in 
Materials and Methods. (B) Working model showing how serum and O2˙ˉ can potentially 
regulate cell survival. Despite being able to enhance survival, serum does not affect O2˙ˉ  






3.3.3 Superoxide promotes Bcl-xL expression 
The dephosphorylation of Bad is an important event that preludes apoptosis in 
LNCaP. The role of dephosphorylated Bad in disrupting Bcl-xL and Bak interaction is 
key to allowing activated Bak to oligomerize with Bax, resulting in MOMP. 
LY294002 has been shown to be able to dephosphorylate Bad as well as induce Bax 
activation. However, despite the activation of both Bax and Bak, LY294002 treatment 
is unable to induce apoptosis in the presence of serum. The importance of Bcl-xL can 
be seen from Figure 13, where its silencing resulted in an increase in caspase 3 
activity. In addition, Bcl-xL plays a key role in serum dependent survival, where its 
upregulation (Figure 17) prevented apoptosis by increasing the availability of 
additional Bcl-xL proteins for the sequestration of Bak (Yang et al., 2003; Sun et al., 
2008). Thus, we question if the pro-survival effects of O2˙ˉ had any relation to Bcl-xL 
overexpression. 
LNCaP cells were serum starved for 24 hours before treatment with DPI, DDC 
or both for 3 hours before harvesting for Western blot analysis. Figure 24A showed 
that cells grown in serum starved media had lower levels of Bcl-xL expression as 
compared to cells grown in medium containing serum. A densitometric analysis was 
performed on three separate Western blots (Figure 24B). This is consistent with 
findings that attribute the pro-survival effect of serum to Bcl-xL overexpression 
(Yang et al., 2003; Sun et al., 2008). The addition of DPI resulted in the 
downregulation of Bcl-xL that was independent of serum presence. However, this 
downregulation could be prevented by co treatment with DDC. This suggests that 





Figure 24: Superoxide promotes Bcl-xL expression 
(A) LNCaP cells were serum starved for 24 hours, followed by incubation with serum, 6µM 
DPI and/or 1mM DDC for 3 hours. The cells were then harvested and lysed for Western blot 
analysis of Bcl-xL and β-actin levels. The gel presented is a representation of three 
independent blots. (B) A densitometric analysis was performed on the 3 sets of Western blots. 
The intensity of Bcl-xL bands were normalized over the loading control. The result shown is 






3.3.4 Superoxide maintains Bad phosphorylation 
The similarities between serum and O2˙ˉ in maintaining survival suggest that it 
could be possible for O2˙ˉ to maintain Bad phosphorylation in a similar fashion to 
serum. To investigate if O2˙ˉ could maintain Bad phosphorylation, LNCaP cells were 
serum starved for 24 hours prior to treatment with DPI and/or DDC with or without 
serum for 1 hour. The cells were then harvested and lysed, followed by Western blot 
analysis. Figure 25A shows that in the absence of DPI or DDC, Bad remained 
phosphorylated. The addition of DPI resulted in dephosphorylation of Bad that was 
independent of serum. The addition of DDC reversed the effect, restoring Bad 
phosphorylation. Bad was also phosphorylated when treated with DDC alone, and 
treatment with DPI or DDC did not result in changes in Bad expression. 
The lysates collected from the above treatment were also subjected to a Bad 
sandwich ELISA assay. The lysates were loaded on a plate coated with Bad 
antibodies that would capture Bad proteins in the lysates. Antibodies specific for 
phosphorylated Bad (ser75) were added subsequently to detect the amount of 
phosphorylated Bad in each sample. The detection antibodies were then recognized by 
HRP conjugated secondary antibodies, which allows for colormetric quantification 
following the addition of TMB substrate. Figure 25B shows that similar to the 
Western blot analysis, treatment with DPI resulted in a reduced level of Bad 
phosphorylation that can be rescued by the addition of DDC. The presence of serum 
did not affect the dephosphorylation induced by DPI treatment, as shown in Figure 
25C. DPI treatment also resulted in the reduction of phosphorylated Bad which can be 




These findings were consistent with the Bad kinase assay, which involves the 
loading of lysates into wells containing Bad substrates available for phosphorylation. 
The phosphorylation is then measured by determining the amount of phosphorylated 
Bad in each well using phospho-Bad antibodies and assessing absorbance. Lysates 
obtained from the above experiments were also analysed for kinase activity for Bad 
phosphorylation. DPI treatment resulted in lowered kinase activity that was reversible 
by the co-treatment with DDC in the absence of serum (Figure 25D). The use of DDC 
alone did not result in a decrease in Bad kinase activity. Similarly, DPI treatment in 
the precence of serum resulted in lowered kinase activity for Bad phosphorylation that 
could be reversed by DDC (Figure 25E). These results indicate that kinase activity for 
Bad phosphorylation is maintained by O2˙ˉ. Taken together, these results suggest that 
O2˙ˉ  is involved in the maintenance of the activity of one or more kinases involved in 















Figure 25: Superoxide maintains Bad phosphorylation 
(A) LNCaP cells were subjected to 24 hour serum deprivation followed by treatment with 
6µM DPI and/or 1mM DDC for one hour in the presence or absence of serum. The cells were 
subsequently harvested and lysed, followed by Western blot analysis to determine the amount 
of Bad phosphorylation. The gel is a representation of 3 independent experiments. (B) Lysates 
of cells treated in serum free conditions from the above were used for analysis of Bad 
phosphorylation using a Bad ELISA assay as described in Materials and Methods. Results 
shown are mean ± S.E. of three independent experiments done in duplicates. (C) Lysates of 
cells treated in serum from the above were used for analysis of Bad phosphorylation using a 
Bad ELISA assay. Results shown are mean ± S.E. of three independent experiments done in 
duplicates. (D) Lysates of cells treated in serum free conditions were also used to assess 
kinase activity for Bad phosphorylation using an in vitro kinase assay as described in 
Materials and Methods. Results shown are mean ± S.E. of three independent experiments 
done in duplicates. (E) Lysates from the corresponding treatment in serum were used to assess 
kinase activity for Bad phosphorylation. Results shown are mean ± S.E. of three independent 









Pim-1 phosphorylates Bad at serine 75 in LNCaP 
The importance of Bad dephosphorylation in permitting apoptosis in LNCaP 
can be seen from the results presented; EGF, R1881, serum and O2˙ˉ all maintain Bad 
phosphorylation and prevent apoptosis in LNCaP cells. It should be noted that Bad 
function is regulated by the phosphorylation of three residues; serine 75 (murine 
equivalent: serine 112), serine 99 (murine equivalent: serine 136), and serine 118 
(murine equivalent: serine 155) (Eisenmann et al., 2003). The phosphorylation of Bad 
results in its interaction with the chaperone 14-3-3, resulting in its sequestration and 
inability to translocate to the mitochondria (Datta et al., 2000). Bad phosphorylation 
at the different residues is highly specific; Akt phosphorylates Bad at serine 99, RSK1 
and Pim-1 kinase phosphorylates Bad at serine 75, PKA phosphorylates Bad at serine 
118 (Datta et al., 2000). However, it was recently shown that phosphorylated serine 
99 and 118 cannot be detected in LNCaP (Chao and Clément, 2006), implying that 
serine 75 residue is the key residue in determining Bad localization in LNCaP cells. 
Previously, our lab had demonstrated the involvement of RSK1 in EGFR mediated 
signaling in Bad phosphorylation (Chao and Clément, 2006), and more recently, we 
also showed that Pim-1 was involved in the phosphorylation of Bad at serine 75 by 
R1881 (Kumar et al., 2011). Therefore, the role of Pim-1 in O2˙ˉ mediated Bad 
phosphorylation will be investigated next.  
Quercetagetin is highly specific inhibitor of Pim-1 kinase activity (Holder et 
al., 2007), and was used in this study to determine if Pim-1 is indeed the kinase 
responsible for O2˙ˉ dependent Bad phosphorylation. It binds reversibly to the ATP-
binding sites of Pim-1 competitively, thus inhibiting its kinase activity. Cell lysates 




phosphorylation using Western blotting. Figure 26A shows a representative blot 
indicating that treatment with quercetagetin resulted in reduced phosphorylated Bad in 
the absence of serum. On the contrary, the presence of serum resulted in an increase 
in phosphorylated Bad in untreated cells. A densitometric analysis was performed on 
the blots (Figure 26B). Upon the addition of quercetagetin, Bad phosphorylation is 
decreased, regardless of presence of serum. These results show that inhibition of Pim-
1 by quercetagetin resulted in a decrease in Bad phosphorylation and can inhibit Bad 
















Figure 26: Pim-1 can phosphorylate Bad at serine 75 in LNCaP 
(A) LNCaP cells were subjected to 24 hour serum deprivation followed by treatment with 
25µM quercetagetin in the presence (SQ) or absence of serum (NSQ) for one hour. The cells 
were subsequently harvested and lysed, followed by Western blot analysis to determine the 
amount of Bad phosphorylation. The gel is a representation of 3 independent experiments. (B) 
A densitometric analysis was performed on the 3 sets of Western blots. The intensity of the 
phosphorylated Bad was normalized over the corresponding total Bad detected. The result 






Mechanism of Pim-1 inhibition by quercetagetin differs from O2˙ˉ  regulation  
Data so far has shown that Pim-1 activity can influence Bad serine 75 
phosphorylation in LNCaP cells. Inhibition of Pim-1 kinase by quercetagetin can 
prevent the increase in Bad phosphorylation by serum. Since serum and O2˙ˉ are 
possibly promoting survival by targeting the same pathway, it would be logical to 
question if the maintenance of Bad phosphorylation by O2˙ˉ is Pim-1 dependent. This 
was achieved by comparing the effects of serum, quercetagetin and DPI in reducing 
Bad phosphorylation. In this experiment, LNCaP cells were subjected to serum, 
quercetagetin and DPI treatment after 24 hours of serum deprivation, after which they 
were harvested and lysed. The cells were harvested at 1, 2 and 4 hours after treatment 
and Western blot analysis, ELISA and Bad kinase activity assay were performed on 
the cell lysates.  
Consistent with previous data, presence of serum maintained Bad 
phosphorylation whilst the absence of serum resulted in a slight decrease on the 
Western blot (Figure 27A). The addition of DPI resulted in a substantial decrease in 
Bad phosphorylation, whereas the use of quercetagetin only reduced phosphorylated 
Bad levels to that seen with no serum treatment. Treatment with DPI led to a decrease 
in phosphorylated Bad levels which could not be prevented by the presence of serum. 
In contrast, the dephosphorylation of Bad induced by quercetagetin could be mitigated 
by the presence of serum. Also, the magnitude of dephosphorylation induced by DPI 
treatment was much larger than that induced by quercetagetin or removal of serum, 
suggesting that the loss of O2˙ˉ has a more drastic effect on Bad phosphorylation than 




To compare the effects of DPI and quercetagetin on Bad phosphorylation, 
lysates obtained from serum starved LNCaP cells treated with DPI and quercetagetin 
in the absence of serum for 1 hour were subjected to a Bad ELISA and kinase assay 
for Bad phosphorylation. The treatment of cells with DPI and quercetagetin resulted 
in a decrease in Bad phosphorylation, but DPI could induce a greater decrease in Bad 
phosphorylation (Figure 27B). However, while DPI was able to lower kinase activity 
for Bad phoshorylation, treatment with quercetagetin did not result in a decrease in 
kinase activity (Figure 27C).  
The same experiment using the same drugs was conducted on cells treated 
with serum. Similarly, Bad phosphorylation was assessed by the Bad ELISA assay 
and kinase activity was assessed using the kinase activity assay for Bad 
phosphorylation. Treatment with DPI and quercetagetin in the presence of serum 
resulted in a decrease in Bad phosphorylation (Figure 27D). However, the decrease in 
Bad phosphorylation induced by DPI was of a larger magnitude than that obtained 
from quercetagetin treatment. Also, the co treatment of DPI and quercetagetin 
resulted in a further decrease in Bad phosphorylation, suggesting that DPI and 
quercetagetin were possibly influencing different targets. This was also evident in the 
kinase assay; DPI treatment resulted in a decrease in kinase activity whereas 
quercetagetin treatment did not elicit a decrease (Figure 27E). 
These results suggest that quercetagetin did not have a significant effect on the 
inhibition of total kinase activity for Bad phosphorylation. It is also logical to assume 
that there are more than one kinase maintaining the phosphorylation of Bad (serine 
75) in LNCaP cells. DPI on the other hand, appeared to be able to reduce Bad 




in maintaining Bad phosphorylation, by maintaining the kinase activity of one or 
more kinases. Despite the ability of quercetagetin to lower Bad phosphorylation, it 
was unable to significantly lower kinase activity. However, it must be accounted that 
the cell lysates had undergone many rounds of washing during the process of the 
assay. Hence, it was possible that the effects of quercetagetin on the inhibition of 
kinase activity were no longer detectable during the time of assay. This also implies 
that the inhibitory effects of DPI were more permanent and could still be maintained 
despite many rounds of washing. The additive effects of DPI and quercetagetin in 
decreasing Bad phosphorylation further suggests that DPI and quercetagetin had 


























Figure 27: DPI, quercetagetin and removal of serum can lower phosphorylated Bad 
levels 
(F) Serum, DPI and quercetagetin could influence Bad phosphorylation in LNCaP cells. Bad 
phosphorylation at serine 75 in LNCaP can be maintained by Pim-1 kinase and possible other 
kinases. Quercetagetin can lower Bad phosphorylation by inhibiting Pim-1 kinase. Serum can 
also maintain Bad phosphorylation, but the removal of serum does not lead to a dramatic 
decrease in Bad phosphorylation. The reduction of intracellular O2˙ˉ levels by DPI is able to 
drastically lower Bad phosphorylation, by possibly lowering kinase activity of Pim-1 kinase 











Dephosphorylation of Bad by quercetagetin bypasses serum protection 
The importance of Pim-1 in maintaining Bad phosphorylation can be affirmed 
by investigating the effects it has in maintaining cell survival. Caspase 3 activity 
assays were carried out to determine if inhibition of Pim-1 does indeed result in cell 
death. LNCaP cells were serum deprived for 24 hours prior to treatment with 
LY294002 and/or quercetagetin for 6, 12 and 24 hours before harvesting for caspase 3 
activity assay. Synergistic treatment of DPI with quercetagetin resulted in caspase 3 
activity even higher than that induced by LY294002 in the absence of serum (Figure 
28A). This suggests that the combination of DPI and quercetagetin is more lethal than 
LY294002 induced cell death. Since DPI and quercetagetin was shown earlier to be 
capable of dephosphorylating Bad, their ability to induce cell death in the absence of 
serum was questioned. However, Figure 28B shows that despite their ability to 
dephosphorylate Bad, DPI and quercetagetin could not induce an increase in caspase 
3 activity even without the pro-survival effects of serum. This indicates that 
dephosphorylation of Bad alone is not sufficient to induce apoptosis in LNCaP cells. 
Interestingly, despite their inability to induce high caspase 3 activity individually, the 
combined treatment of DPI and quercetagetin resulted in an increase in caspase 3 
activity (Figure 28B), suggesting that O2˙ˉ and Pim-1 maintain key components in 
LNCaP survival. 
In a separate experiment, LNCaP cells were serum deprived for 24 hours prior 
to treatment with LY294002 and/or quercetagetin for 6, 12 and 24 hours before 
harvesting for caspase 3 activity assay. Treatment with LY294002 in the absence of 
serum (NS+LY) resulted in high caspase 3 activity. Although the presence of serum 




was able to bypass the protective effects of serum (Figure 28C). In contrast, treatment 
with just quercetagetin in the presence of serum (S+Q) did not result in an increase in 
caspase 3 activity as seen with LY294002 treatment. This is similar to the earlier 
finding where like DPI, quercetagetin is able to overcome the protective effects of 
serum but unable to induce cell death without LY294002 co treatment. Taken 
together, these results imply that the maintenance of Bad phosphorylation by Pim-1 is 
vital to ensuring LNCaP survival, but the dephosphorylation of Bad is insufficient to 
induce apoptosis. Indeed, only the inhibition of both Pim-1 dependent Bad 



















Figure 28: Dephosphorylation of Bad by quercetagetin bypasses serum protection 
(A) LNCaP cells were serum deprived for 24 hours before treatment with 25µM LY294002 
(LY), 6µM DPI (DPI) and/or 25µM quercetagetin (Q) for 6-24 hours in the presence of 
serum. The cells were then harvested and lysed, and lysates were assessed for caspase 3 
activity normalized over protein concentration in the lysates. The inclusion of LY294002 
treatment in absence of serum (NS+LY) serves as a positive control. (B) LNCaP cells were 
serum deprived for 24 hours before treatment with 25µM LY294002 (NS+LY), 6µM DPI 
(NS+DPI) or 25µM quercetagetin (NS+Q) for 6-24 hours in the absence of serum. The cells 
were then harvested and lysed, and lysates were assessed for caspase 3 activity normalized 
over protein concentration in the lysates. (C) LNCaP cells were serum deprived for 24 hours 
before treatment with 25µM LY294002 in the presence (S+LY) or absence of serum 
(NS+LY), 25µM quercetagetin in serum (S+Q), and combined LY294002 and quercetagetin 
treatment in serum (S+Q+LY) for 6-24 hours. The cells were then harvested and lysed, and 
lysates were assessed for caspase 3 activity normalized over protein concentration of the 
lysates.  (D) Serum promotes survival in LNCaP cells by maintaining Bad phosphorylation, 
increasing Bcl-xL expression and preventing Bax activation. However, the inhibition of Pim-
1 by quercetagetin was able to overcome the pro-survival effects of serum and sensitize 





Inhibition of Pim-1 by quercetagetin in the absence of Akt results in high caspase 3 
activity 
The role of Pim-1 as a key kinase in the alternative survival pathway was 
investigated next using a molecular approach, by silencing Akt expression and 
downregulating the PI3K-Akt axis. LNCaP cells were transfected with siRNA 
specific for Akt before treatment with quercetagetin. The cells were harvested at 6, 12 
and 24 hours and lysed for caspase 3 activity analysis. The action of the PI3K-Akt 
independent survival pathway is evident as the silencing of Akt did not induce an 
increase in caspase 3 activity in the presence of serum (Figure 29A). However, upon 
treatment with quercetagetin, caspase 3 activity increased to similar levels induced by 
LY294002. This indicates that Pim-1 is indeed playing a crucial role in defining the 
alternative survival pathway. 
In addition, knockdown of Akt expression resulted in the cells’ inability to 
survive in media without serum. Figure 29B shows that in the absence of serum, cells 
with silenced Akt exhibited increased caspase 3 activity as compared to the control. It 
must be noted that the conditions of the cells at this point was very poor, and these 
cells also could not survive serum starvation. The lysates obtained for this treatment 
yielded much less protein than the other samples.  
Treatment of LNCaP cells with LY294002 led to a decrease in Bad 
phosphorylation at serine 75 (Figure 29C). Silencing of Akt with gene specific siRNA 
also led to a decrease in Bad phosphorylation (Figure 29D). These results imply that 
the dephosphorylation of Bad at serine 75 is a result of loss of Akt activity. However, 
as Akt is not known to phosphorylate Bad at serine 75, it would appear that Akt is 




maintaining Bad phosphorylation at serine 75 has been examined in the earlier 
section. Interestingly, Akt and Pim-1 are both key kinases that cooperatively regulate 
partially overlapping apoptotic and metabolic pathways (Amaravadi and Thompson, 
2005), and are commonly found to be deregulated in prostate cancer. Pim-1 and Akt 
both share several similarities; the most obvious being their preferred substrate motif 
of RxRxxS. Pim-1 is a constitutively active kinase and its activity is largely dependent 
on expression rather than phosphorylation (Bachmann and Möröy, 2005; Ma et al., 
2007; Mizuno et al., 2001; Qian et al., 2005; Qian et al., 2005). In addition, both Pim-
1 as well as Akt contain the substrate motif RxRxxS, which could possibly be sites for 
Pim-1 and Akt cross phosphorylation. However, the relationship between Pim-1 and 
















Figure 29: Inhibition of Pim-1 by quercetagetin in the absence of Akt results in high 
caspase 3 activity 
(A) LNCaP cells were transfected with siRNA specific for Akt (siAkt) and control siRNA for 
48 hours before treatment with 25µM quercetagetin in the presence of serum (SQ) for 6-24 
hours. The cells were then harvested and lysed, and lysates were assessed for caspase 3 
activity normalized over protein concentration in the lysates. The insert shows the level of 
Akt silencing 48 hours following transfection with the respective siRNAs. (B) In the same 
experiment, LNCaP cells transfected with siRNA specific for Akt (siAkt) were incubated in 
serum free media for 6-24 hours (siAkt NS). Cells transfected with control siRNA were 
treated using 25µM LY294002 (NS+LY) for 6-24 hours. The cells were then harvested and 
lysed, and lysates were assessed for caspase 3 activity normalized over protein concentration 
in the lysates. (C) LNCaP cells were serum deprived for 24 hours before treatment with 25µM 
LY294002 in serum free media (NS+LY) for one hour. The cells were subsequently harvested 
and lysed, followed by Western blot analysis to determine the amount of Bad 
phosphorylation. The gel is a representation of 3 independent experiments. (D) LNCaP cells 
were transfected with increasing concentrations of siRNA specific for Akt. A mock 
transfection without siRNA was included as control. The levels of Bad phosphorylation at 











3.3.5 Superoxide prevents Bax activation 
Superoxide prevents Bax activation  
 Bax and Bak are key pro-apoptotic proteins that effect MOMP. As discussed 
earlier, the loss of both Bax and Bak severely impairs the ability of LNCaP to undergo 
apoptosis. Hence, the Bax/Bak activation parameter defined previously will be 
investigated. Detection of Bax activation was achieved by using a mouse antibody 
that recognizes the N-terminus of the Bax protein (anti-Bax6A7). LNCaP cells were 
treated with LY294002, DPI and/or DDC for 12 and 24 hours in the presence and 
absence of serum, followed by harvesting and fixation. The fixed cells were 
permeabilized, allowing the bulky antibody to enter the cells to bind to activated Bax 
proteins. Following an overnight incubation, the cells were permeabilized again to 
allow secondary antibodies with conjugated FITC to enter. The cells were then 
analyzed for FITC fluorescence using a flow cytometer, and cell profiles obtained 
were analyzed for Bax activation using WINMDI 2.8. 
 Figure 30A shows that normal untreated control cells grown in media 
supplemented with serum had a low percentage of activated Bax. The pro-survival 
effect of serum can be seen when LY294002 treated cells in media with serum did not 
show significant changes in Bax activation compared to the control. However, the 
protective effects of serum could be bypassed by the addition of DPI which lowers 
intracellular O2˙ˉ levels. The increase in percentage of activated Bax induced by DPI 
can be prevented by co-treatment with DDC which restores O2˙ˉ levels, highlighting 
the importance of O2˙ˉ in promoting LNCaP survival. The data obtained from the flow 










Figure 30: DPI sensitizes LNCaP cells to cell death by causing Bax conformational 
change 
(A) LNCaP cells were serum starved for 24 hours before treatment with fresh growth medium 
with 10% serum (S), LY in 10% serum (S+LY), DPI in 10% serum (S+DPI) and LY and DPI 
in 10% serum (S+DPI+LY) with and without DDC, for 12 hours and 24 hours. Bax activation 
was determined by flow cytometry as described in Materials and Methods. The percentage of 
cells with activated Bax was analyzed using WINMDI 2.8. Representative profiles of Bax and 









Superoxide prevents intracellular acidification 
While the activation of Bax involves conformational changes, it is unclear 
how Bax activation can be induced. As discussed previously, there are many models 
in Bax/Bak activation in the scientific field, and the major disagreement between the 
models is how Bax is activated. The direct activation model states that Bax activation 
is induced by BH3-only proteins directly, whereas the displacement model believes 
that Bax is constitutively active and is kept dormant by sequestration by pro-survival 
Bcl-2 proteins (Chipuk and Green, 2008). Interestingly, Bax activation has also been 
shown to be influenced by changes in intracellular pH (Khaled et al., 2001; Tafani et 
al., 2002; Ahmad et al., 2004). In addition, there have been many reports 
demonstrating the importance intracellular acidification as an early event leading to 
the creation of a permissive milieu for apoptosis (Clément et al., 1998; Liu et al., 
2000; Pervaiz and Clément, 2002). This suggests that there is a possible link between 
intracellular pH regulation and Bax activation. 
Apart from an alteration in Bcl-2 family protein regulation, cancer cells also 
exhibit a unique phenomenon of maintaining a higher pH than normal (Parks et al., 
2011). This confers advantages such as increased inhibition of caspase activity and 
increased transcription activity to the cancer cell. The adaptive changes in cancer cell 
metabolism in response to oxygen and glucose shortage results in an increased 
production of protons that need to be efficiently removed from the intracellular 
environment (Chiche et al., 2010). As ubiquitous sodium proton exchangers, members 
of the NHE family play important roles in maintaining cancer intracellular pH. The 
generic NHE isoform, NHE-1, has been shown to play an important role in several 




migration, as well as survival and apoptosis (Putney et al., 2002). It is thus of great 
importance to investigate the effects of O2˙ˉ on intracellular pH and its possible roles 
in regulating Bax activation. 
LNCaP cells were serum starved for 24 hours before treatment with 
LY294002 and DPI for one hour before analysis using the pH assay. Since all NHE 
isoforms extrude H
+
 by exchanging for Na
+
, the assay does not differentiate between 
the different isoforms of NHE. In this assay, the pHi of the cells was measured in 
cycles of 60 seconds, with the first cycle giving the pHi prior to acid loading (initial 
pHi). The next eight cycles measured the pHi during acid loading with NH4
+
 solution, 
resulting in intracellular alkalinization, due to the influx of NH3 and subsequently 
NH4
+
 into the cytosol. Next, the cells were washed with Na
+
 free buffer. The lack of 
Na
+




, thus causing the cytosol to remain saturated 
with H
+
. Upon returning the cells to normal Na
+
 containing buffer, NHE starts its 
pump activity at maximum capacity due to the saturation of H
+
, allowing an accurate 
determination of NHE activity. The recovery from the acid load was measured in the 
next 15 cycles, with the activity defined as the change in pH change in time over the 
first 2 cycles. The pH of the first cycle in the recovery phase gives the pH at which 
the pump begins to extrude H
+
. The absence of bicarbonate in the buffers used in this 










DPI induced acidification can be rescued by DDC 
Figure 31A shows the profile of the pH assay, with the first minute being the 
initial pHi measurement, the second to ninth minute the acid loading phase, and tenth 
minute and beyond the recovery phase. As defined above, the NHE activity is the 
gradient over the first 2 cycles in the recovery phase. Figure 31A shows that NHE 
activity was unaffected by DPI or LY294002 treatment, as the gradients were similar. 
LNCaP cells have a pH of 7.6 (Figure 31B) when grown in medium with serum. The 
addition of DPI, which reduces O2
˙ˉ
 levels, decreases the pHi from 7.6 to 7.2, causing 
intracellular acidification. This effect was amplified by the addition of LY294002, 
resulting in a further decrease of 0.2 in pH. The addition of DDC, which results in the 
increase of intracellular O2
˙ˉ
 levels, neutralizes the acidification, restoring the pH to 
the physiological value of 7.6. This rescue effect was in place even in the presence of 
LY294002. The sensitivity of NHE to acidification was investigated next, as NHE 
with lowered sensitivity to acidification would only begin proton extrusion at a much 
lower pH, allowing the accumulation of H
+
. Figure 31C shows a similar trend to 
Figure 31B, with DPI lowering the sensitivity and DDC being able to restore it. 
Similarly, LY294002 has a universal effect of lowering proton affinity independent of 
other drug treatments. Taken together, these results suggest that DPI and LY294002 
treatment resulted in the lowering of NHE proton affinity as well as inducing 
intracellular acidification. The effects of DPI however, can be reversed by DDC, 
indicating that O2
˙ˉ








Figure 31: DPI induced intracellular acidification can be rescued by DDC 
LNCaP cells were serum starved for 24 hours, followed by treatment with 25µM LY294002, 
6µM DPI and/or 1mM DDC for 1 hour. The intracellular pH of the cells were analyzed by 
BCECF dye via the pH assay described in Materials and Methods. (A) The pH profile of cells 
treated with 25µM LY294002 in the absence of serum (NS+LY), 6µM DPI with (S+DPI+LY) 
or without 25µM LY294002 (S+DPI) is presented. The first pH value obtained represents the 
intracellular pH, while the gradient of the profile from the 10
th
 minute indicates the rate of 
extrusion of protons. (B) The intracellular pH of the cells subjected to the above treatments is 
shown. Data presented is mean of 3 independent experiments ± S.E. (C) The pH value of the 
10
th
 minute represents the pH at which NHE begins proton extrusion. The values of the cells 
subjected to the above treatments are shown. Data presented is mean of 3 independent 





















 levels results in intracellular acidification, it was important 
to address if intracellular acidification was sufficient to shut down this AKT 
independent survival pathway. This was done by using EiPa, an effective general 
inhibitor of NHE that inhibits all NHE isoforms (Masereel et al., 2003). NHE 
inhibitors work by competitively binding to the extracellular Na
+
 binding region, thus 
blocking the exchange of intracellular H
+
 for extracellular Na
+
. 
From Figure 32A, it can be seen that EiPa is an efficient inhibitor of NHE 
activity, bringing down not only the pH, but also lowering NHE sensitivity to 
acidification (Figure 32C) and inhibiting NHE activity. Due to the proton affinity and 
NHE pump activity being severely compromised by EiPa, the intracellular pH of 
LNCaP is lowered significantly (Figure 32B). Hence, EiPa is able to mimick the 











Figure 32: Inhibition of NHE by EiPa results in intracellular acidification and lowers 
pH at which NHE begins proton extrusion 
LNCaP cells were serum starved for 24 hours, followed by treatment with 25µM LY294002 
and/or 50µM EiPa for 1 hour. The intracellular pH of the cells were analyzed by BCECF dye 
via the pH assay described in Materials and Methods. (A) The pH profile of cells treated with 
50µM EiPa in the presence (S+E+LY) and absence of 25µM LY294002 (S+E), 6µM DPI 
with 25µM LY294002 (S+DPI+LY) is presented. The first pH value obtained represents the 
intracellular pH, while the gradient of the profile from the 10
th
 minute indicates the rate of 
extrusion of protons. (B) The intracellular pH of the cells subjected to the above treatments is 
shown. Data presented is mean of 3 independent experiments ± S.E. (C) The pH value of the 
10
th
 minute represents the pH at which NHE begins proton extrusion. The values of the cells 
subjected to the above treatments is shown. Data presented is mean of 3 independent 




Next, to investigate the effects of EiPa treatment on cell cytotoxicity, sub-G1 
populations of LNCaP cells were analyzed. LNCaP cells were grown in media with 
serum and treated with EiPa and/or LY294002 for 24 hours before harvesting and 
fixing for cell cycle profiling. Cells treated with EiPa alone were healthy, as indicated 
by the low sub-G1 population (Figure 33A). The protective effect of serum was 
evident when LY294002 was added, as the sub-G1 population remained low 
compared to cells treated with EiPa and LY294002. Figure 33B shows the cell cycle 
profile of the respective treatments. In summary, EiPa was able to remove the 
protective effects of serum against LY-induced cell death, demonstrating that EiPa 
could also shut down the PI3K-Akt independent survival pathway. 
EiPa treatment alone did not elicit high levels of caspase 3 activity, indicating 
that the inhibition of NHE activity and lowering of intracellular pH was insufficient in 
inducing caspase 3 activation. However, when LY294002 was used with 50μM of 
EiPa (S+50E+LY), the amount of caspase 3 activity was similar to that of the positive 
control of combined DPI and LY294002 treatment (S+DPI+LY) (Figure 33C). This 
provides strong evidence that the maintenance of NHE activity by O2
˙ˉ
 is vital in 
preventing apoptosis, providing an alternative survival pathway should the PI3K-Akt 












Figure 33: Inhibition of NHE by EiPa removes protective effect of serum against 
LY294002 induced cell death 
LNCaP cells were serum starved for 24 hours, followed by treatment with 25µM LY294002 
with or without 50µM EiPa for 24 hours. The cells were then harvested and fixed for 
propidium iodide (PI) staining. The percentage of cells in sub-G1 phase was derived by 
analyzing the cell cycle profiles on a flow cytometer. Results shown are a mean of three 
independent experiments done in duplicates ± S.E. (B) Cell cycle profiles of the above 
treatment. M1: sub-G1 phase, M2: G1 phase, M3: S phase, M4: G2/M phase. (C) LNCaP 
cells were treated with LY294002 for 2-24 hours following 24 hours of serum deprivation. 
The cells were then harvested and lysed, and lysates were assessed for caspase 3 activity 
normalized over protein concentration in the lysates. Results shown are mean ± S.E. of three 












Inhibition of NHE by EiPa results in Bax activation 
Since EiPa and DPI could both induce intracellular acidification, which 
creates a permissive milieu for apoptosis to occur, it was imperative to define if 
acidification resulting from inhibition of NHE by EiPa could induce Bax activation. 
This was achieved by using a mouse antibody that recognizes the N-terminus of the 
Bax protein (anti-Bax6A7). Fixed cells were permeabilized, allowing the bulky 
antibody to enter the cells to bind to activated Bax proteins. Following an overnight 
incubation, the cells were permeabilized again to allow secondary antibodies with 
conjugated FITC to enter. These antibodies which are specific for mice antigens only 
recognize and bind to the Bax antibodies, providing a means to quantify the amount 
of Bax present in cells. The cells were then analyzed for FITC fluorescence using a 
flow cytometer, and results normalized against normal untreated cells.  
LNCaP cells were treated with EiPa for 24 hours before performing the Bax 
activation assay. Figure 34A shows the profile of cells measured for FITC 
fluorescence using a flow cytometer. The FITC values of the cell population were 
recorded and presented as the number of events against FITC value. A greater FITC 
value indicates a greater amount of fluorescence detected, indicating a higher amount 
of activated Bax present in the cells. The distribution of the population of cells gives 
an indication of the staining efficiency; a completely stained sample would contain 
most cells with the same amount of FITC, giving a well defined and narrow peak. In 
this experiment, the staining was complete and the signal obtained was not a result of 
background fluorescence (Figure 34A). LY294002 and EiPa treatment resulted in an 
increase in Bax activation as compared to the untreated control. The synergistic 














Figure 34: EiPa treatment results in increased Bax activation 
(A) Serum starved LNCaP cells were subjected to 50µM EiPa treatment and/or 25µM 
LY294002 treatment in the presence of serum (NS+LY) for 24 hours. The cells were 
harvested and fixed, followed by permeabilization and incubation with anti-Bax6A7 primary 
antibodies overnight. This was followed by incubation with secondary FITC conjugated 
antibodies. The relative amount of activated Bax was measured from the mean of FITC 
fluorescence for each sample. The data presented represents the mean of three independent 
experiments ± S.E. in duplicates. (B) The profiles of unstained cells (background control), 
untreated control (S) and cells treated with 50µM EiPa (S+E) is shown. The high resolution 
observed for each sample indicates complete staining, as well as a distinct increase in FITC 





Inhibition of NHE-1 by cariporide induces acidification but not caspase 3 activity  
NHE-1 is ubiquitously expressed, and shown to play important roles in 
coverall cellular functions, including cell proliferation, cytoskeletal reorganization, 
cell migration as well as survival and apoptosis (Putney et al., 2002; Meima et al., 
2007). Cariporide is a specific inhibitor of NHE-1, and was shown to induce 
intracellular acidification to sensitize cytotoxic breast cancer cells to death (Wong et 
al., 2005). To determine if the acidification and Bax activation induced by EiPa was 
attributed to NHE-1 function, cariporide was used to specifically inhibit NHE-1. 
Upon treatment of serum deprived cells with cariporide for one hour, cells were 
subjected to the pH assay. Treatment with cariporide resulted intracellular 
acidification and reduction in proton extrusion activity (Figure 35A) similar to that 
induced by EiPa.  
LNCaP cells were also serum starved for 24 hours prior to treatment with 
cariporide, EiPa, DPI or LY294002. The cells were harvested after 2, 4, 12 and 24 
hours of treatment and the caspase 3 activity of the lysates obtained determined using 
the caspase assay. Contrary to results from Figure 33C, the addition of cariporide to 
LY294002 did not result in high caspase 3 activity (Figure 35B). Furthermore, 
treatment with cariporide, unlike EiPa, did not result in an increase in the percentage 
of cells in sub-G1 phase (Figure 35C). Due to its specific inhibition on NHE-1, the 
inability of cariporide in removing the protective effects of serum against LY-induced 
apoptosis indicates that NHE-1 did not play an important role preventing apoptosis by 
serum. In addition, it was likely that there were other isoforms of NHE in LNCaP 









Figure 35: Inhibition of NHE-1 by cariporide results in intracellular acidification but is 
unable to sensitize cells to LY294002 induced cell death 
LNCaP cells were serum starved for 24 hours, followed by treatment with 25µM LY294002 
and/or 50µM cariporide for 1 hour. The intracellular pH of the cells were analyzed by BCECF 
dye via the pH assay described in Materials and Methods. (A) The pH profile of cells treated 
with 50µM cariporide in the presence (S+C+LY) and absence of 25µM LY294002 (S+C), 
6µM DPI with 25µM LY294002 (S+DPI+LY) is presented. The first pH value obtained 
represents the intracellular pH, while the gradient of the profile from the 10
th
 minute indicates 
the rate of extrusion of protons. (B) LNCaP cells were treated with LY294002 for 2-24 hours 
following 24 hours of serum deprivation. The cells were then harvested and lysed, and lysates 
were assessed for caspase 3 activity normalized over protein concentration in the lysates. (C) 
LNCaP cells were serum starved for 24 hours, followed by treatment with 50µM EiPa (E) or 
cariporide (C)with or without 25µM LY294002 for 24 hours. The cells were then harvested 
and fixed for propidium iodide (PI) staining. The percentage of cells in sub-G1 phase was 


















NHE isoforms in prostate tissue and LNCaP cells 
To address the difference in ability to sensitize LNCaP cells to LY294002 
induced apoptosis between EiPa and cariporide, the expression of the NHE isoforms 
in LNCaP cells had to be understood. It was reported that out of the 9 NHE isoforms, 
NHE isoforms 1, 2 and 3 are expressed in prostate tissue cells (Steffan et al., 2009). 
The detection of the NHE isoforms was achieved by assessing the presence of the 
NHE mRNAs. LNCaP cells grown in 10% FBS were harvested and their mRNA was 
extracted. A reverse transcription reaction was performed, followed by PCR using 
primers designed for each isoform. The amplified cDNAs were run on a DNA agarose 
gel, where the NHE-1 and NHE-2 samples were observed to give a distinct band 
(Figure 36). A negative control was performed using only the primers without any 
template to check for primer dimers. β-actin was also used as a loading control. 
Results from Figure 36 indicate that NHEs 1 and 2 but not NHE-3 are expressed in 












Figure 36: NHE isoform expression in LNCaP 
LNCaP cells grown to 70% confluency were harvested. RNA extraction was performed, 
followed by reverse transcription. The cDNA obtained was amplified using primers for the 3 
NHE isoforms using PCR, and analyzed on an agarose gel. β-actin was used as a loading 














Loss of NHEs 1 and 2 results in acidification and impairment in proton extrusion 
capacity 
Since NHE isoforms 1 and 2 are expressed in LNCaP cells and the specific 
inhibition of NHE-1 by cariporide did not sensitize LNCaP cells to LY294002 
induced cell death, the two isoforms are seemingly playing different roles in serum 
mediated LNCaP survival. To investigate the specific roles of NHE-1 and NHE-2 in 
LNCaP survival, gene knockdown by siRNA was performed on both NHE isoforms. 
However, NHE-2 detection on Western blotting was unsatisfactory despite using 
antibodies from 2 different companies. To circumvent this problem, the mRNA levels 
of NHE-2 were assessed to determine silencing efficiency. Following that, the 
transfected cells were analyzed for differences in their pH profile to determine if 
either isoform was playing a more pronounced role than the other.  
LNCaP cells were transfected with gene specific siRNA specific for NHE-1 
and NHE-2 for 48 hours before analysis of intracellular pH using the pH assay. Figure 
37A shows the effective silencing of NHE-1 and NHE-2, as well as the pH profile of 
the transfected cells. It can be seen that the loss of NHE-2 resulted in greater 
acidification as compared to NHE-1, as well as a greater loss in recovery upon acid 
loading. Figure 37B shows the pH profile of cells with silenced NHEs 1 and 2. 
Silencing of NHE-1 did not appear to jeopardize the cell’s ability to regulate pH, but 
NHE-2 silencing was more effective in lowering intracellular pH and recovery. The 
data points from this profile is presented in Figure 37C which shows that the pH of 
cells transfected with siRNA specific for NHEs 1 and 2 decreased, with the loss of 
NHE-2 resulting in a greater decrease in pH. The pH at which NHE begins proton 




greater decrease than NHE-1 (Figure 37D). This indicated that NHE-2 played a more 
effective role in the regulation of pH and extrusion of protons upon acid loading in 








Figure 37: Loss of NHEs 1 and 2 results in intracellular acidification 
(A) LNCaP cells transfected with control siRNA and siRNA specific for NHEs 1 and 2 for 48 
hours. The efficiency of siRNA silencing was assessed by PCR for NHE-2 and Western 
blotting for NHE-1 (B) The cells were subjected to the pH assay as described in Materials and 
Methods, and the profile obtained is shown. NHE activity is defined by the gradient at 10min 
onwards. (C) The intracellular pH value of the cells was obtained from the first reading of the 
pH profile. (D) The 10
th










Loss of NHE-2 resulted in increased Bax activation 
Since the previous results have established the expression of NHEs and their 
respective roles in maintaining intracellular pH, the next question to ask would be if 
the difference in pH regulation could contribute to a difference in Bax activation. If 
either of the NHE isoforms were to be involved in preventing Bax activation, the loss 
of that particular isoform would result in an increase in Bax activation. To address 
this, LNCaP cells transfected with NHEs 1 and 2 specific siRNAs were harvested and 
fixed, before incubating with Bax6A7 antibodies. The Bax activation assay was 
completed and the cells were analyzed for activated Bax via a flow cytometry. The 
fluorescence obtained was normalized against that obtained from the control siRNA 
transfected cells. 
Figure 38A shows the dotplots of the cell populations for the various 
treatments. The cell populations were highly concentrated at one region, indicating 
homogeneity in cell size and granularity. The population profiles of each sample were 
well defined and resolved, indicating complete staining of the samples. The profiles 
were superimposed together in a representative graph (Figure 38B), showing that the 
unstained cells had minimal fluorescence. Also, there was a shift towards the right for 
the profile of cells with NHE-2 silencing as compared to cells transfected with control 
siRNA (Figure 38B). The mean values of each profile was obtained and normalized 
against cells transfected with control siRNA, and the values were presented in Figure 
38C. Treatment with EiPa resulted in an increase in Bax activation which can also be 
seen in cells transfected with siNHE-2.  Transfection with siNHE-1 did not result in 
an increase in Bax activation but the silencing of both NHE isoforms resulted in an 









Figure 38: Loss of NHE-2 results in increased Bax activation 
(A) LNCaP cells were transfected with control siRNA and siRNA specific for NHEs 1 and 2 
for 48 hours. The cells were harvested and fixed, followed by permeabilization and incubation 
with anti-Bax6A7 primary antibodies overnight. This was followed by incubation with 
secondary FITC conjugated antibodies. The relative amount of activated Bax was measured 
from the mean of FITC fluorescence for each sample. Cells treated with 50µM EiPa was used 
as a positive control. The data presented represents the mean of three independent 
experiments ± S.E. in duplicates. (B) The profiles of unstained cells (background control), 
untreated control (S) and cells treated with 50µM EiPa (S+E) is shown. The high resolution 
observed for each sample indicates complete staining, as well as a distinct increase in FITC 





NHE-2 prevents Bax activation and intracellular acidification 
Also, to ascertain that the increase in Bax activation was the only parameter 
affected by NHE silencing, the other main axis for survival, Bad phosphorylation was 
investigated. This was to ensure that Bax activation from NHE-2 silencing was not a 
result of increased activation of Bad. Bad phosphorylation was assessed via Western 
blotting; lysates obtained from cells with silenced NHEs 1 and 2 were obtained and 
analyzed on a Western blot (Figure 39A). A positive control of LY294002 was used 
to induce Bad dephosphorylation. It can be clearly seen that the loss of neither NHE-1 
nor NHE-2 resulted in Bad dephosphorylation, indicating that the increase in Bax 
activation due to NHE-2 was not due to a decrease in Bad phosphorylation.  
These data show that loss of NHE-2 but not NHE-1 results in an increase in 
Bax activation, implying that NHE-2 is required for preventing Bax activation in 
LNCaP cells. Also, despite both NHE-1 and NHE-2 being able to regulate 
intracellular pH, only the loss of NHE-2, either by silencing or inhibition by EiPa, 
could induce an increase in Bax activation. In addition, the loss of either NHE-1 or 
NHE-2 did not result in acidification of the magnitude induced by DPI treatment. 
Clearly, NHE-2 dependent Bax activation was not mediated by intracellular 
acidification. This suggests that intracellular acidification is not linked to Bax 
activation, and that NHE-2 prevents Bax activation by a mechanism that does not 






Figure 39: NHE-2 prevents Bax activation and intracellular acidification 
(A) LNCaP cells were transfected with control siRNA and siRNA specific for NHEs 1 and 2 
for 48 hours followed by harvesting and lysis. The lysates were analyzed for Bad 
phosphorylation using Western blotting. LY294002 treatment was used as a positive control 
for Bad phosphorylation. (B) NHE-1 and NHE-2 could both prevent intracellular 
acidification, but only NHE-2 was involved in preventing Bax activation. The prevention of 






Pim-1 inhibition by quercetagetin has no effect on pH and NHE activity 
Since NHE-2 dependent Bax activation was not mediated by intracellular 
acidification, it would be logical to question how NHE-2, whose primary function is 
pH regulation, could be involved in the activation of Bax. Studies on NHE-1 have 
shown that NHE-1 is involved in secondary cellular functions such as Akt activation 
and cell adhesion (Putney et al., 2002). These secondary functions can be attributed to 
the post translational modifications of its cytoplasmic C-terminal domain, allowing 
interactions with proteins from other cellular pathways. This cytoplasmic C-terminal 
domain contains several phosphorylation sites that allow modifications that would 
lead to a change in sensitivity to acidity or rate of extrusion of protons. Akt has been 
reported to phosphorylate serine 648 and serine 703 of NHE-1 (Meima et al., 2009). 
These serine residues are preceded by the preferred substrate motif for Akt, RxRxxS 
(Figure 40). In addition, further examination of the NHE-2 protein sequence revealed 
that the regulatory C-terminal domain also contains this motif. The fact that Pim-1 
and Akt both share the same substrate recognition motif led to the question of whether 






Figure 40: Cytoplasmic C-terminus amino acid sequences of NHE isoforms expressed in 
LNCaP 
The regulatory cytoplasmic C-terminus domains of NHE isoforms 1, 2 and 3 contain the 
RxRxxS motif (highlighted regions), which is the preferred substrate recognition motif for 
both Akt and Pim-1.  
 
The role of Pim-1 in NHE-mediated regulation of intracellular pH was 
investigated next. LNCaP cells were serum deprived for 24 hours before treatment 
with quercetagetin in the presence or absence of serum. Figure 39A shows that 
treatment with quercetagetin in the presence of serum did not result in any changes in 
intracellular pH. The experiment was repeated with cells treated in the same 
conditions except in serum free media. Quercetagetin treatment in the absence of 
serum resulted in a decrease in intracellular pH, and a decrease in proton extrusion 
capacity (Figure 41B). These results suggest that Pim-1 was not playing a major role 







Figure 41: Quercetagetin inhibition of Pim-1 has no effect on pH and NHE activity 
(A) LNCaP cells were serum starved for 24 hours before treatment with 25µM quercetagetin 
for 1 hour in the presence of serum. The cells were then subjected to the pH assay as 
described in Materials and Methods, and the profile obtained is shown. (B) Serum deprived 
LNCaP cells were treated with 25µM quercetagetin for 1 hour in serum free media. The cells 
were then subjected to the pH assay as described in Materials and Methods, and the profile 






To further investigate the specificity of Pim-1 on the NHE isoforms, 
quercetagetin was applied to LNCaP cells transfected with either siNHE-1 or siNHE-
2. To achieve this, LNCaP cells were transfected with NHEs 1 and 2 siRNAs for 48 
hours prior to treatment with quercetagetin in the absence of serum for an hour. The 
intracellular pH of the cells was then determined using the pH assay. Figure 42A 
shows that the loss of NHE-1 did not result in intracellular acidification, but the 
addition of quercetagetin resulted in a decrease in pH and NHE proton affinity. In 
comparison, the loss of NHE-2 alone led to a decrease in intracellular pH, as well as a 
decrease in proton extrusion activity (Figure 42B) that was exacerbated by the 
addition of quercetagetin. Figure 42C compares the intracellular pH of LNCaP cells 
following silencing of NHE-1 and NHE-2, as well as treatment with quercetagetin. 
The silencing of NHE-2 but not NHE-1 resulted in intracellular acidification. 
Treatment with quercetagetin in the absence of NHE-2 did not result in further 
acidification, suggesting that quercetagetin induced acidification was mediated by 
NHE-2 
In summary, these results demonstrate that NHE-2 was the more important 
isoform in the maintenance of intracellular pH in LNCaP cells. This was achieved by 
NHE-2 maintaining a high rate of proton extrusion. While the pH of LNCaP cells is 
maintained more by NHE-2, the causative link between intracellular acidification and 
Bax activation cannot be established. Despite this, the assessment of intracellular 
acidification remains a useful indication of NHE-2 activity which also prevents Bax 
activation. Although NHE-2 has been proven to be vital in the prevention of Bax 













Figure 42: NHE-2 plays a more important role in the regulation of pH in LNCaP than 
NHE-1 
(A) LNCaP cells were transfected with siNHE-1 for 48 hours before treatment with 25µM 
quercetagetin for 1 hour in the absence of serum. The cells were then subjected to the pH 
assay as described in Materials and Methods, and the profile obtained is shown. (B) LNCaP 
cells were transfected with siNHE-2 for 48 hours before treatment with 25µM quercetagetin 
for 1 hour in the absence of serum. The cells were then subjected to the pH assay as described 
in Materials and Methods, and the profile obtained is shown. (C) The intracellular pH of the 
treatments is obtained from the pH value of the first minute. Results presented are mean of 




 In summary, the results shown in this chapter demonstrate the existence and 
importance of the PI3K-Akt independent survival pathway in maintaining LNCaP cell 
survival. This survival pathway has been shown to be mediated by three important 
parameters: Bad phosphorylation, Bcl-xL overexpression and Bax/Bak activation and 
translocation. The results also show that O2˙ˉ is vital in the maintenance of survival by 
regulating all three parameters. Furthermore, Pim-1 and NHE-2 have been identified 







Figure 43: Death circuitry in LNCaP 
LY294002 shuts down the PI3K-Akt survival pathway in LNCaP, inducing apoptosis in the 
absence of serum. There is a PI3K-Akt independent survival pathway that is maintained by 
O2˙ˉ, which maintains Bad phosphorylation, upregulates Bcl-xL and prevents Bax activation. 
The shutting down of both pathways result in efficient cell death in LNCaP. The primary 











CHAPTER 4: DISCUSSION 
4.1 SUPEROXIDE MAINTAINS PI3K-AKT INDEPENDENT SURVIVAL IN 
LNCAP CELLS 
4.1.1 EGF, R1881 and serum prevents LY294002 induced in LNCaP cells 
The PI3K-Akt signaling pathway is one of the most important survival 
pathways in cancer cells. This commonly altered survival pathway is of great 
importance especially in prostate cancer, where a loss of function of PTEN, the 
antagonist of PI3K signaling, results in a constitutively active state. This has led to an 
assumption that the shutting down of this pathway would be effective in the 
development and progression of prostate cancer. An example of such an approach is 
the use of perifosin, which was shown to decrease Akt activation and induce apoptosis 
in many prostate cancer as well as many other cell lines (Ruiter et al., 2003; 
Hideshima et al., 2006; Li et al., 2006). Unfortunately, when perifosine was used in 
phase II trials, it did not confer any significant therapeutic benefits to patients with 
hormone refractory prostate cancer (Posadas et al., 2005). A possible explanation for 
this is that cancer cells, especially those in the later stages of development, usually 
possess mutations in several pathways that function synergistically or redundantly to 
prevent apoptosis and promote survival. The existence of other survival pathways and 
their development has in fact led to an increase in resistance to further therapy. 
As defined previously in this report, the PI3K-Akt independent survival 
pathway in LNCaP is largely dependent on the Bcl-2 family proteins and their 
regulation of MOMP. The four main parameters defined are: 




2. Bcl-xL overexpression 
3. Bax/Bak translocation and activation 
The known agents that are able to prevent LY294002 induced apoptosis in LNCaP 
include serum, R1881 and EGF, and the mechanism of their pro-survival effects was 
investigated. In summary, these agents could influence one or more of the 4 defined 
parameters and prevent MOMP.  
 
4.1.2 Superoxide promotes survival independently from PI3K-Akt pathway 
Cancer cells live in an abnormal tumour microenvironment which plays an 
important role in determining cancer cell metabolism. The non uniformity and 
inefficiency of tumour vasculature and the intrinsic metabolic alterations of cancer 
cells lead to high levels of spatial and temporal inconsistencies in the distribution of 
oxygen, pH, glucose and metabolites which cancer cells must adapt to. Cancer cells 
are often reported to exhibit higher than normal levels of ROS, which correlates 
positively to the aggressiveness and resistance to chemotherapy. This is especially 
true in prostate cancer, where it was reported that prostate malignancy and 
progression can be attributed to oxidative stress (Dakubo et al., 2006; Khandrika et 
al., 2009). Other groups have also suggested that the high levels of oxidative stress in 
cancer cells support proliferation and survival, while at the same time providing a 
permissive milieu for mutagenic events that will drive tumourigenesis (Cairns et al., 
2011). High levels of antioxidants ensure that the cancer cells maintain a redox 





The results shown in this report demonstrate that there exists a O2˙ˉ mediated 
survival pathway that is independent of PI3K-Akt signaling. By decreasing 
intracellular O2˙ˉ levels, LNCaP cells can be sensitized to LY294002 induced 
apoptosis; which could be reversed by increasing O2˙ˉ levels. This was in agreement 
with a recent study that prostate cancer cell lines exhibit higher levels of O2˙ˉ as 
compared to their normal counterparts (Kumar et al., 2008). It must be noted that the 
manipulation of intracellular O2˙ˉ levels, which was achieved by the use of DPI and 
DDC, could lead to other non specific effects, such as H2O2 production by DPI and 
the inhibition of oxidative phosphorylation in the mitochondria. H2O2 production was 
analyzed and it was found that while the use of DPI resulted in H2O2 production, the 
inability of DDC to remove this indicates that the increase in H2O2 by DPI was most 
likely inconsequential. Also, while it is likely that death induced by DPI after 24 
hours of treatment could be attributed to the inhibition of oxidative phosphorylation, 
the ability of DDC to delay caspase activation adds further weight that O2˙ˉ plays an 
important role in maintaining survival. 
The production of O2˙ˉ in prostate cancer cell lines PC3, DU145 and LNCaP 
was found to be from NOX complexes rather than from the electron transport chain in 
the mitochondria (Kumar et al., 2008). The group also reported an increase in NOX 
expression in the prostate cancer cell lines as compared their normal counterparts. A 
screening on NOX expression in LNCaP by our group also showed that NOX 2 and 4 
are present, with NOX 4 being present in larger amounts. (Appendix A) However, 
attempts to silence NOX 4 proved to be challenging, as different siRNAs used were 




the NOX complexes in LNCaP would no doubt provide additional specificity and 
insights to understanding this pathway.  
Although the sources of O2˙ˉ and their pro-survival effects have been 
established, the mechanism by which O2˙ˉ promotes survival is unclear. Results 
shown in this report have demonstrated that O2˙ˉ and serum are independent from 
each other; regulating similar targets to promote cell survival. O2˙ˉ was found to be 
able to overcome serum protection against LY294002 induced cell death by playing a 
prominent role in maintaining Bad phosphorylation, Bcl-xL expression and 
preventing Bax activation. This enables O2˙ˉ to effectively prevent MOMP and play 
an important role in maintaining the PI3K-Akt independent survival pathway in 
LNCaP. 
 
4.2 SUPEROXIDE MAINTENANCE OF BAD PHOSPHORYLATION IS PIM-
1 MEDIATED 
One of the most important roles of O2˙ˉ in mediating LNCaP survival is the 
maintenance of Bad phosphorylation. Results shown in this report have highlighted 
the crucial role of O2˙ˉ in maintaining Bad phosphorylation; DPI treatment resulted in 
a dramatic reduction in Bad phosphorylation levels. DPI treatment was also more 
effective than quercetagetin and serum withdrawal in lowering Bad phosphorylation 
levels. In addition, DPI could lower kinase activity despite the repeated washing 
involved in the assay. These findings suggest that O2˙ˉ could either be regulating more 
than one kinase or was influencing kinase activity via a more permanent post 




The BH3-only protein, Bad, plays an important role in the activation of 
apoptosis by allowing Bax/Bak formation by sequestering Bcl-xL. Apart from this 
function, Bad has been shown to involved in metabolism; with its phosphorylation 
status directly correlating to glucokinase activity (Danial et al., 2003). Bad was found 
to be co-localized in the mitochondria together with glucokinase, where maximum 
glucokinase activity was dependent on Bad phosphorylation. Since cancer cells rely 
heavily on anaerobic respiration and glycolysis for ATP production, Bad 
phosphorylation not only prevents apoptosis, but also ensures a constant supply of 
energy production. The phosphorylation of Bad can be achieved via a multitude of 
kinases. Of the 3 serine residues that are phosphorylated, serine 75 appears to be the 
single most important residue in the LNCaP system. We had previously demonstrated 
that serine 99, the preferred residue phosphorylated by Akt, was undetectable in 
LNCaP (Chao and Clément, 2006). Serine 75 phosphorylation can be attributed to 
kinases such as RSK1, RSK2 and Pim-1 kinase (Aho et al., 2004; del Peso et al., 
1997; Fang et al., 1999; Harada et al., 1999; Scheid et al., 1999; She et al., 2002; Yu 
et al., 2004; Zhang et al., 2004). Since we had previously demonstrated that the 
involvement of RSK in the phosphorylation of Bad was attributed to EGFR signaling, 
Pim-1 appeared to be the only other kinase capable of phosphorylating serine 75.  
The importance of Pim-1 can also be seen from the fact that Pim-1 has been 
reported to be involved in the development of prostate cancer (Wang et al., 2010; 
Zemskova et al., 2008). In fact, to understand the molecular upstream regulators and 
downstream targets, a molecular approach of silencing Pim-1 was performed using 
gene specific siRNA in this study. However, repeated attempts using various siRNAs 




1 were then assessed, and it can be seen that the siRNA did in fact lower mRNA 
expression levels (Appendix B). The half-life of Pim-1 was reported to be 100 
minutes (Shay et al., 2005), but the silencing experiments performed went up to 72 
hours without seeing a decrease in Pim-1 expression, highlighting the importance of 
Pim-1 in LNCaP. 
Since it was not possible to silence Pim-1 in LNCaP, the next best alternative 
would be to use the specific inhibitor of Pim-1 kinase, quercetagetin. Quercetagetin is 
a highly specific inhibitor of Pim-1 kinase activity (Holder et al., 2007); it was able to 
lower Bad phosphorylation in LNCaP cells. The ability of quercetagetin and DPI to 
lower Bad phosphorylation in LNCaP is an indication that O2˙ˉ mediated Bad 
phosphorylation is possibly Pim-1 dependent.  
 
4.3 PIM-1 ACTIVITY CAN BE REGULATED BY SUPEROXIDE 
Interestingly, while the reduction in O2˙ˉ levels consistently led to Bad 
dephosphorylation, a loss in Bad kinase activity was not detected upon inhibition by 
quercetagetin. In addition, the magnitudes of Bad dephosphorylation for DPI and 
quercetagetin was very different. Serum also seemed to be able to influence Bad 
phosphorylation, albeit on a smaller scale similar to that induced by quercetagetin. It 
must be noted that the concentration of quercetagetin used in this study was much 
higher than that used for non tumourigenic models. Despite the seemingly larger dose 
used, the magnitude of inhibition remained low. Taken together, these findings 
suggest that lowering of Pim-1 activity by competitive inhibition may be insufficient 




4.3.1 Pim-1 half life and stability are increased in LNCaP cells 
Despite the inability to lower Pim-1 expression, our group had demonstrated 
that R1881-induced increase in Pim-1 activity correlated with an increase in Pim-1 
half life (Kumar et al., 2011). Indeed, it has been shown that inhibition of the 26S 
proteasome prevents Pim-1 degradation and the half life of Pim-1 increases with 
proteasomal inhibition (Shay et al., 2005). In contrast, silencing of Pim-1 in MEF was 
easily achieved using the same methodology, suggesting that the stability of the Pim-1 
protein had been increased in LNCaP.  
Pim-1 stability had been shown to be enhanced by Hsp90 (Mizuno et al., 
2001). Shay et al had also succeeded in immunoprecipitating Hsp90 with Pim-1, as 
well as showing that Pim-1 could bind to Hsp90 and Hsp70 in vivo. Crystal structure 
analysis of Pim-1 also shed light on the function of Pim-1 in vivo. Pim-1 kinase is 
monomeric and does not contain a regulatory domain, hence degradation rather than 
steric hindrance was a more plausible mechanism for downregulation (Qian et al., 
2005). In addition, the reported structures of Pim-1 also highlighted that the 
interaction between Pim-1 and its inhibitors were weak, thus explaining the transient 
nature of quercetagetin mediated inhibition seen in this study (Qian et al., 2005).  
 
4.3.2 Redox regulation of Pim-1 activity 
Apart from proteosome mediated degradation, Pim-1 was also shown to be 
negatively regulated by PP2A (Ma et al., 2007). Phosphorylated Pim-1 binds to an 
isomerase (Pin-1) that allows its interaction and dephosphorylation by PP2A which 




peroxynitrite derived from nitric oxide and O2˙ˉ was able to nitrate PP2A and 
influence its activity (Wu and Wilson, 2009). Taken together, there is possibly a direct 
correlation to Pim-1 regulation by O2˙ˉ.  
The relative ease of silencing Pim-1 in MEF cells and the high dosage of 
quercetagetin required for effective Pim-1 inhibition compared to non-carcinogenic 
cell lines suggest that the enhanced stability of Pim-1 was a unique phenomenon in 
LNCaP cells. In view of the evidence presented by various groups, it would appear 
that the regulation of Pim-1 activity is dependent on a balance between an increase in 
degradation or enhancement of its stability. In LNCaP, this balance appears to be 
more in the favour of an increase in Pim-1 stability. The ability of O2˙ˉ to influence 
Pim-1 activity and the possible role of redox regulated PP2A in the regulation of Pim-
1 suggest that this balance could possibly be shifted by O2˙ˉ levels. The increased 
stability results in a longer half-life which allows Pim-1 to maintain Bad 
phosphorylation and hence promote survival.  
The enhanced stability could also have resulted in an increase in Pim-1 
activity which was more resilient to quercetagetin inhibition. This would account for 
the need of a higher dose of quercetagetin in LNCaP as compared to non-carcinogenic 
cell lines to achieve inhibition. This would also explain the inability of quercetagetin 
to exert a more permanent effect on Pim-1, as seen in this study. Quercetagetin is 
likely to inhibit the unstable form of Pim-1 more effectively, but the stabilization of 
Pim-1 by Hsp90 results in the inefficiency of quercetagetin and enhances the activity 
of Pim-1. 
It would seem that the increase in O2˙ˉ levels detected as well as Pim-1 being 




from this study as well as reports from several groups point to scenario where O2˙ˉ 
favours the formation of Hsp90-Pim-1 complex, allowing for the prolonged half-life 
and enhanced activity of Pim-1. A good starting point to investigate this would be to 
use DPI and DDC to disrupt and restore the interaction between Pim-1 and Hsp90. 
This can be achieved by using co-immunoprecipitation experiments, where lysates 
obtained from LNCaP cells treated with DPI and/or DDC would be analysed for 
Hsp90-Pim-1 interaction. To further test this hypothesis, the experiment could be 
repeated using other non-carcinogenic cell lines to determine if there is a difference in 
Hsp90-Pim-1 interaction. 
 
4.4 AKT SILENCING CAN DECREASE BAD SER75 PHOSPHORYLATION 
It is interesting to note that Pim-1 and Akt are both key kinases in prostate 
cancer development and progression. The similarities between the pair does not end 
here; both kinases share very similar substrate preference for basic residues at 
positions -5 and -3, and a small side chain at +1 (Bullock et al., 2005). Both Akt and 
Pim-1 share substrates such as Bad, p21, and Cot/Tpl-2, playing redundant roles in the 
regulation of cell growth and survival. Although both kinases are able to 
phosphorylate Bad, the target residue on Bad is different for Akt and Pim-1, with 
Pim-1 targeting serine 75 and Akt phosphorylating serine 99. It would appear that 
there are secondary selectivity for residues at other positions (Hutti et al., 2004), 
which allow the segregation of target residues of both kinases.  
It was also found, in this study that the silencing of Akt resulted in a decrease 




of maintaining Bad phosphorylation was Pim-1, suggesting an involvement of Akt in 
the regulation of Pim-1 activity. Also, it was reported that LY294002, a PI3K 
inhibitor, was able to downregulate Pim-1 activity, although the mechanism involved 
was unknown (Jacobs et al., 2005). It is likely that Akt and Pim-1, by virtue of their 
common substrate preferences, could have overlapping and redundant roles. 
 
4.5 NON-PH REGULATION FUNCTIONS OF NHE 
One of the targets of Akt containing the preferred substrate motif of Pim-1 is 
NHE-1 (Meima et al., 2009). NHEs play an important role in the regulation of 
intracellular pH. This is especially important in cancer cells given their aberrant 
metabolism, so as to limit and prevent excessive acidification due to glycolysis and 
lactic acid production (Chiche et al., 2010). Apart from pH regulation, NHE-1 has 
been shown to be involved in other non-pH related functions such as cell-cell 
adhesion, migration, proliferation and survival (Putney et al., 2002). The relationship 
between Akt and NHE-1 has also been elucidated; NHE-1 was shown to be involved 
in cell-cell adhesion via complex formation with ERM (Wu et al., 2004), whilst Akt 
was also recently shown to phosphorylate NHE-1 at serine 548 and serine 703 of its 
regulatory C-terminal domain (Meima et al., 2009). Indeed, these positions on NHE-1 
fulfilled the requirements for Pim-1 substrate preference, with arginine residues at the 
-5 and -3 positions and a small side chain at +1 residue. Similar sequences can also be 
found in the C-terminal domains of NHE-2 and NHE-3, the other 2 isoforms 
expressed in prostate cells. Hence, it is very likely that NHE-2 and NHE-3 are not 




4.6 MAINTENANCE OF NHE-2 FUNCTION IS ESSENTIAL FOR 
PREVENTION OF BAX ACTIVATION 
The important roles NHEs play in cell survival in LNCaP was highlighted 
when the generic NHE inhibitor, EiPa, was used in this study. Interestingly, the 
effective inhibition of NHE required a high dosage of EiPa, which was required to be 
present in the buffers used in the pH assays as well. This was also true for the NHE-1 
specific inhibitor, cariporide. This suggests that the activity of NHEs were greatly 
enhanced and were in an active state, possibly in response to the constant production 
of H+ in cancer cells. It was interesting that while both inhibitors were able to lower 
pH and inhibit NHE activity, only EiPa was able to sensitize LNCaP cells to LY-
induced apoptosis. This led to the investigation of the distinction of function between 
the 2 isoforms detected in LNCaP cells, as well as the role they played in cancer 
development. 
The specific inhibition of NHE-1 by cariporide did not sensitize LNCaP cells 
to LY-induced apoptosis because NHE-2 was responsible for the prevention of Bax 
activation. Silencing of the NHE-1 and NHE-2 resulted in increased Bax activation in 
the latter but not the former, suggesting that NHE-2 but not NHE-1 was responsible 
for preventing Bax activation. In addition, the loss of NHE-2 resulted in a greater loss 
in LNCaP cells’ ability to recover from acidification, resulting in a more acidic 
environment as compared to the loss of NHE-1. While it is clear that acidification did 
not necessarily led to Bax activation, it is evident that the presence of NHE-2 was 
vital in the prevention of Bax activation. However, it is unclear at this point if the pH 




 It must be noted that both the loss of NHE-2 and its inhibition by EiPa 
sensitized LNCaP cells to LY294002 induced cell death. However, the inhibition of 
NHE-2 by EiPa does not remove the availability of NHE-2 for protein interactions. A 
possible approach would be to investigate if the silencing of NHE-2 and/or NHE-1 
can sensitize the cells to LY294002 induced apoptosis. The other key moderators of 
apoptosis in LNCaP are Bad, Bak and Bcl-xL. Bax activation alone has been shown to 
be insufficient to induce apoptosis in LNCaP. It would be interesting to investigate the 
effects of NHE inhibition or silencing on each of these proteins, in particular Bak 
which shares many similarities in activation and function with Bax. 
 
4.7 PIM-1 MEDIATED REGULATION OF NHE-2 
Having shown that Pim-1 is possibly the effector of O2˙ˉ signaling in the redox 
dependent survival pathway, the next logical step would be to question the 
involvement of Pim-1 in NHE-2 mediated Bax activation. NHE-2 contains the 
preferred substrate sequence of Pim-1, and is in all likelihood a substrate of Pim-1. As 
NHE-1 also share similar sequences, the selectivity and specificity of Pim-1 for either 
of the 2 isoforms was investigated. Due to the inability to downregulate Pim-1 protein 
expression, the next best option was to utilize quercetagetin to find out if it could 
further lower intracellular pH or lower proton extrusion rate. Our data also show that 
the addition of quercetagetin to cells with silenced NHE-1 or NHE-2 resulted in a 
further decrease in pH as well as set point. This suggests that Pim-1 was involved in 
the regulation of both NHEs, maintaining extrusion activity and preventing 




as opposed to O2˙ˉ regulation discussed earlier, this finding is inconclusive and 
requires Pim-1 downregulation to provide additional evidence. 
 
4.8 SUPEROXIDE IS AN IMPORTANT MEDIATOR OF LNCAP SURVIVAL 
Pim-1 appeared to be an important effector of O2˙ˉ in the regulation of the 
apoptotic machinery in LNCaP. Its ability to maintain Bad phosphorylation and 
regulate NHE activity is vital in the prevention of Bcl-xL inactivation and Bax 
activation. Despite this, the inactivation of Pim-1 alone is insufficient in shutting 
down the alternative survival pathway, as demonstrated in this study. Indeed, the 
nature of the various overlapping survival pathways in prostate cancer meant that the 
shutting down of one pathway would always be insufficient to elicit an efficient 
trigger of apoptosis. This study has demonstrated clearly that O2˙ˉ plays a key and 
vital role in the maintenance of the alternative PI3K-Akt survival pathway. This is 
achieved primarily via the genomic level of increasing Bcl-xL expression, as well as 
via the enhancement of Pim-1 stability and activity, resulting in an efficient 
sequestration of Bad by 14-3-3, as well as the prevention of Bax activation. This 
results in less Bak and Bax activation, which manifests as a resistance to apoptotic 
triggers. 
The O2˙ˉ mediated pathway is important because it controls three of the 
defined parameters of the apoptotic program: Bcl-xL overexpression, Bad 
phosphorylation and Bax activation. It can be seen that neither the dephosphorylation 
of Bad by Pim-1 inhibition nor the increase in Bax activation by EiPa resulted in 




an efficient execution of apoptosis. The decrease of O2˙ˉ levels can achieve not only 
both Bad dephosphorylation and Bax activation, but also induce a decrease in Bcl-xL 
expression, further enhancing the efficiency of MOMP by allowing effective Bax and 
Bak activation. The role of this O2˙ˉ mediated survival pathway can be seen when the 
reduction of O2˙ˉ, when coupled with the shutting down of the PI3K-Akt pathway, 
resulted in extensive cell death even in the presence of serum (Figure 43). 
 
4.9 POTENTIAL APPLICATIONS 
 The work presented here was performed exclusively using the prostate cancer 
cell line, LNCaP. The findings illustrated may not necessarily be representative of all 
other prostate cancer cell lines. Unfortunately, due to the lack of availability of human 
prostate cancer cell lines, the LNCaP cell line remains relevant as a tool for 
investigating prostate cancer, especially in understanding early androgen sensitive 
prostate cancer. LNCaP is the only prostate cancer cell line that is androgen sensitive, 
capable of mimicking prostate cancer progression (Sobel and Sadar, 2005). LNCaP 
derived cell lines also share similarities with clinical prostate cancer; shifting away 
from androgen dependence and having similar preferred metastatic patterns 
(Thalmann et al., 2000). Moreover, since few animals spontaneously develop prostate 
cancer, translation to in vivo models can be challenging. While the impact of the work 
presented here could be enhanced by using more cell lines and/or in vivo models, it 
provides a good foundation upon which more investigation can be done.  
 Recently, redox chemotherapeutics have become increasingly popular 




inhibitors as awell as thioredoxin inhibitors. There is also an increasing number of 
drugs moving into human clinical trials. In addition, various research groups have 
begun targeting NOX dependent ROS generation for redox therapy as it becomes 
increasingly clear that O2˙ˉ can promote survival (Wondrak, 2009). Specifically, in a 
study involving breast cancer in mouse models, SOD mimetics could lower 
superoxide levels and kill cancer cells (Weydert et al., 2006). This is in agreement 
with results shown in this project: O2˙ˉ promotes survival; reduction in O2˙ˉ can 

















Mutations in key survival and proliferation pathways are hallmarks of cancer. 
Increasingly, cancer progression and aggressiveness have been found to correlate 
positively with mild but higher than normal levels of oxidative stress, which is 
increasingly accepted to play a role in enhancing survivability and chemoresistance. 
More importantly, the differentiation of the different ROS in this oxidative stress has 
led to the finding that O2˙ˉ plays a key role in the enhancement of survival. Presently, 
prostate cancer prognosis remains poor, with current monotherapy targeting the 
commonly mutated PI3K-Akt pathway proving ineffective. Increasing evidence 
attributing prostate cancer aggressiveness to O2˙ˉ underlines the need for a deeper 
understanding of O2˙ˉ mediated survival in prostate cancer cells. The findings 
presented in this study have established that O2˙ˉ maintains survival by preventing 
Bax/Bak activation through three mechanisms: increasing Bcl-xL expression, 
maintaining Bad phosphorylation at serine 75 and preventing Bax activation via an 
NHE-2 mediated pathway. We have also, for the first time, demonstrated that NHE-2 
is required for Bax activation in LNCaP cells. There was also evidence to show that 
the primary effector of O2˙ˉ signaling is Pim-1, maintaining Bad phosphorylation and 
possibly NHE-2 function. This was in agreement with findings that Pim-1 is also a 
prognostic marker in prostate cancer, providing a framework on how O2˙ˉ, Pim-1 and 
Akt could possibly interact with one another to evade apoptosis and enhance cell 
survival. 
Since an increase in oxidative stress is not restricted to only prostate cancer, 
but is observed in many cancers, the work presented in this study could provide a 




cancer cells exhibit higher levels of oxidative stress, in particular O2˙ˉ, the disruption 
of this redox balance could provide a non-global and cancer cell specific approach to 
sensitize cancer cells to other forms of treatment, resulting in a more effective and 
efficient eradication of cancer cells. Indeed, the understanding and eventual 
manipulation of O2˙ˉ signaling would form the bedrock upon which novel, effective 
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